-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 RDhUdevTdKZyw+4nvlh4vskf08v085Cia8nHpdNiEJhUJ/YwNuKaOuO8QXJpFB+J
 gHT+flKO72N08ZztdYyCnA==

<SEC-DOCUMENT>0001362310-09-005240.txt : 20090413
<SEC-HEADER>0001362310-09-005240.hdr.sgml : 20090413
<ACCEPTANCE-DATETIME>20090413141214
ACCESSION NUMBER:		0001362310-09-005240
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20090512
FILED AS OF DATE:		20090413
DATE AS OF CHANGE:		20090413
EFFECTIVENESS DATE:		20090413

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOGENEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-80623
		FILM NUMBER:		09746364

	BUSINESS ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		4254879500

	MAIL ADDRESS:	
		STREET 1:		1522 217TH PLACE S.E.
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>c83831def14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="center" style="font-size: 14pt; margin-top: 6pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>SCHEDULE 14A</B>
</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 12pt">Proxy Statement Pursuant to Section&nbsp;14(a) of the Securities<BR>
Exchange Act of 1934 (Amendment No. <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Filed by the Registrant <FONT face="wingdings" size="2">&#254;</FONT><BR>
Filed by a Party other than the Registrant <FONT face="wingdings" size="2">&#111;</FONT>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box:

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="1%" nowrap align="left" valign="top">
<FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Preliminary Proxy Statement</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="1%" nowrap align="left" valign="top">
<FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD><B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-</B><B>6(e)(2)</B><B>)</B></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="1%" nowrap align="left" valign="top">
<FONT face="wingdings" size="2">&#254;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Definitive Proxy Statement</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="1%" nowrap align="left" valign="top">
<FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Definitive Additional Materials</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="1%" nowrap align="left" valign="top">
<FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Soliciting Material Pursuant to &#167;240.14a-12</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center" style="font-size: 10pt; margin-top: 6pt">&nbsp;</DIV>

<DIV align="center">
ONCOGENEX PHARMACEUTICALS, INC.</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
(Name of Registrant as Specified In Its Charter)</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 6pt">&nbsp;</DIV>

<DIV align="center">
</DIV>
<DIV align="center" style="font-size: 10pt"><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Payment of Filing Fee (Check the appropriate box):

</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="1%" nowrap align="left" valign="top">
<FONT face="wingdings" size="2">&#254;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>No fee required.</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="1%" nowrap align="left" valign="top">
<FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Fee computed on table below per Exchange Act Rules&nbsp;14a-6(i)(1) and 0-11.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">(1)</TD>
<TD width="1%">&nbsp;</TD>
<TD>Title of each class of securities to which transaction applies:</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD style="font-size: 10pt"><DIV align="left">

</DIV></TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">(2)</TD>
<TD width="1%">&nbsp;</TD>
<TD>Aggregate number of securities to which transaction applies:</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD style="font-size: 10pt"><DIV align="left">

</DIV></TD>
</TR>

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">(3)</TD>
<TD width="1%">&nbsp;</TD>
<TD>Per unit price or other underlying value of transaction computed pursuant to Exchange Act
Rule&nbsp;0-11 (set forth the amount on which the filing fee is calculated and state how it was
determined):</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD style="font-size: 10pt"><DIV align="left">

</DIV></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">(4)</TD>
<TD width="1%">&nbsp;</TD>
<TD>Proposed maximum aggregate value of transaction:</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD style="font-size: 10pt"><DIV align="left">

</DIV></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">(5)</TD>
<TD width="1%">&nbsp;</TD>
<TD>Total fee paid:</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD style="font-size: 10pt"><DIV align="left">

</DIV></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="1%" nowrap align="left" valign="top">
<FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Fee paid previously with preliminary materials.</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="1%" nowrap align="left" valign="top">
<FONT face="wingdings" size="2">&#111;</FONT></TD>
<TD width="1%">&nbsp;</TD>
<TD>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2)
and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its
filing.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">(1)</TD>
<TD width="1%">&nbsp;</TD>
<TD>Amount Previously Paid:</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD style="font-size: 10pt"><DIV align="left">

</DIV></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">(2)</TD>
<TD width="1%">&nbsp;</TD>
<TD>Form, Schedule or Registration Statement No.:</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD style="font-size: 10pt"><DIV align="left">

</DIV></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">(3)</TD>
<TD width="1%">&nbsp;</TD>
<TD>Filing Party:</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD style="font-size: 10pt"><DIV align="left">

</DIV></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">(4)</TD>
<TD width="1%">&nbsp;</TD>
<TD>Date Filed:</TD>
</TR>

<TR>
<TD style="font-size: 6pt">&nbsp;</TD>
</TR>

<TR>
<TD width="2%">&nbsp;</TD>
<TD width="3%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD style="font-size: 10pt"><DIV align="left">

</DIV></TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
<TD width="2%" style="background: transparent">&nbsp;</TD>
<TD width="3%" nowrap align="left">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></TD>
</TR>

</TABLE>
</DIV>

<P align="center" style="font-size: 10pt">
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left">
<!-- TOC -->
</DIV>
<DIV align="left">
<A name="tocpage"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ONCOGENEX PHARMACEUTICALS, INC.<BR>
1522 217th Place S.E. Suite&nbsp;100<BR>
Bothell, Washington 98021<BR>
April&nbsp;13, 2009</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dear Stockholder:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">You are cordially invited to attend the Annual Meeting of stockholders of OncoGenex
Pharmaceuticals, Inc. on Tuesday, May&nbsp;12, 2009, at 10:00&nbsp;a.m. local time. The Annual Meeting will
be held in the Pike Room of the Sheraton Seattle Hotel located at 1400 Sixth Avenue, Seattle,
Washington.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The matters to be acted upon are described in the accompanying Notice of Annual Meeting and Proxy
Statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Your vote is very important. Whether or not you plan to attend the Annual Meeting, we urge you to
vote and submit your proxy by telephone, the Internet or by mail in order to ensure the presence of
a quorum. If you attend the Annual Meeting, you may, of course, revoke your proxy and vote your
shares in person. If you hold your shares through an account with a brokerage firm, bank or other
nominee, please follow the instructions you receive from them to vote your shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We look forward to seeing you at the Annual Meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Sincerely,
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="60%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ SCOTT CORMACK<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt">Scott Cormack<BR>
President and Chief Executive Officer
</DIV>
<DIV align="left">
<!-- /TOC -->
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ONCOGENEX PHARMACEUTICALS, INC.<BR>
1522 217th Place S.E. Suite&nbsp;100<BR>
Bothell, Washington 98021</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders of OncoGenex Pharmaceuticals, Inc.,
a Delaware corporation, will be held on May&nbsp;12, 2009, at 10:00&nbsp;a.m. local time. The Annual Meeting
will be held in the Pike Room of the Sheraton Seattle Hotel located at 1400 Sixth Avenue, Seattle,
Washington, for the following purposes:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To elect six directors to serve until our next annual meeting of stockholders or until their
successors are duly elected and qualified;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To ratify the appointment of Ernst &#038; Young LLP as our independent auditor for the fiscal year
ending December&nbsp;31, 2009; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>To transact such other business as may properly come before the Annual Meeting.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Only stockholders of record at the close of business on March&nbsp;31, 2009 are entitled to notice of,
and to vote at, the Annual Meeting. For ten days prior to the Annual Meeting, a complete list of
stockholders entitled to vote at the Annual Meeting will be available for examination by any
stockholder, for any purpose relating to the Annual Meeting, during ordinary business hours at our
headquarters at the above address.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="40%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By Order of the Board of Directors,</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/S/ STEPHEN ANDERSON
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Stephen Anderson
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><I>Secretary</I></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Bothell, Washington<BR>
April&nbsp;13, 2009

</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>YOUR VOTE IS IMPORTANT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>WHETHER OR NOT YOU PLAN TO ATTEND THE MEETING, WE ENCOURAGE YOU TO VOTE AND SUBMIT YOUR PROXY BY
TELEPHONE, THE INTERNET OR BY MAIL. FOR ADDITIONAL INSTRUCTIONS ON VOTING BY TELEPHONE OR THE
INTERNET, PLEASE REFER TO YOUR PROXY CARD. TO VOTE AND SUBMIT YOUR PROXY BY MAIL, PLEASE COMPLETE,
SIGN AND DATE THE ENCLOSED PROXY CARD AND RETURN IT IN THE ENCLOSED ENVELOPE. IF YOU ATTEND THE
MEETING, YOU MAY, OF COURSE, REVOKE YOUR PROXY AND VOTE IN PERSON. IF YOU HOLD YOUR SHARES THROUGH
AN ACCOUNT WITH A BROKERAGE FIRM, BANK OR OTHER NOMINEE, PLEASE FOLLOW THE INSTRUCTIONS YOU RECEIVE
FROM THEM TO VOTE YOUR SHARES.</B>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#101">PROXY STATEMENT FOR 2009 ANNUAL MEETING OF STOCKHOLDERS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#102">BOARD OF DIRECTORS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#103">General</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">8</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#104">Director Independence</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#105">Relationships Among Directors, Executive Officers and Director Nominees</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#106">Stockholder Communication with the Board</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#107">Related Party Transactions Policy and Procedure</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#108">Board Committees</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#109">Audit Committee and Audit Committee Financial Expert</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#110">Audit Committee Responsibilities</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#111">Compensation Committee</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#112">Nominating and Governance Committee</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#113">Director Nomination Process</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#114">Code of Ethics</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#115">PROPOSAL ONE: ELECTION OF DIRECTORS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#116">Nominees</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">12</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#117">Director Compensation Overview</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#118">Current Director Compensation Policy</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#119">Director Compensation Paid for 2008</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#120">REPORT OF THE AUDIT COMMITTEE</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#121">PROPOSAL TWO: RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#122">Principal Accountant for Previous Fiscal Years</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#123">Fees Billed by Independent Auditors</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#124">Policy on Audit Committee Pre-Approval of Audit Services and Permissible Non-Audit Services</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#125">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">19</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#126">COMPENSATION DISCUSSION AND ANALYSIS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#127">Overview</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#128">Compensation Philosophy and Objectives</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#129">Compensation Review Process and the Role of Executive Officers in Compensation Decisions</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#130">Benchmarking of Executive Compensation</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#131">Elements of Executive Compensation</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#132">Stock Ownership Guidelines</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#133">Perquisites</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#134">2008 Named Executive Officer Compensation</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#135">Other Policies and Considerations</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#136">Compensation Committee Interlocks and Insider Participation</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#137">Report of the Compensation Committee on Executive Compensation</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#138">EXECUTIVE COMPENSATION</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#139">Summary Compensation Table</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#140">Fiscal 2008 Grants of Plan-Based Awards</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#141">Outstanding Equity Awards at Fiscal Year-End</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#142">Option Exercises and Stock Vested</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#143">Pension Benefits/Nonqualified Deferred Compensation</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#144">Potential Payments Upon Termination/Change of Control</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="90%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><A href="#145">OTHER MATTERS</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#146">Section&nbsp;16(a) Beneficial Ownership Reporting Compliance</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#147">Delivery of Documents to Stockholders Sharing an Address</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#148">Stockholder Proposals to be Presented at Next Annual Meeting</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-15px"><A href="#149">Transaction of Other Business</A></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>ONCOGENEX PHARMACEUTICALS, INC.<BR>
1522 217th Place S.E. Suite&nbsp;100<BR>
Bothell, Washington 98021</B>
</DIV>

<DIV align="left">
<A name="101"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>PROXY STATEMENT FOR</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>2009 ANNUAL MEETING OF STOCKHOLDERS</B></DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 10pt">This Proxy Statement is furnished in connection with the solicitation of proxies on behalf of the
Board of Directors of OncoGenex Pharmaceuticals, Inc., a Delaware corporation (the &#147;Company&#148;), for
use at the Annual Meeting of Stockholders to be held on May&nbsp;12, 2009, at 10:00&nbsp;a.m. local time, or
at any adjournment or postponement thereof, for the purposes set forth herein and in the
accompanying Notice of Annual Meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Annual Meeting will be held on May&nbsp;12, 2009 at the Sheraton Seattle Hotel located at 1400 Sixth
Avenue, Seattle, Washington. This Proxy Statement and accompanying proxy card will first be mailed
on or about April&nbsp;13, 2009 to all stockholders entitled to vote at the Annual Meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Voting Rights</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Only stockholders of record at the close of business on March&nbsp;31, 2009, the record date, are
entitled to notice of and to vote at the Annual Meeting and any adjournment or postponement
thereof. At the close of business on March&nbsp;31, 2009, we had 5,549,905 shares of common stock
outstanding and no shares of preferred stock outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Each stockholder of record is entitled to one vote for each share of common stock held on the
record date on all matters. Dissenters&#146; rights are not applicable to any of the matters being voted
upon.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">All stockholders entitled to vote at the Annual Meeting may cumulate the votes in the election of
directors. With cumulative voting, each stockholder is entitled to a number of votes equal to the
number of votes that the stockholder would be entitled to cast for the election of directors with
respect to the stockholder&#146;s shares of stock multiplied by the number of directors to be elected by
the stockholders, and each stockholder may cast all of such votes for a single director or may
distribute them among the number to be voted for, or for any two or more of them. However, no
stockholder will be entitled to cumulate votes unless the name of the candidate or candidates for
whom such votes would be cast has been placed in nomination prior to voting, and any stockholder
has given notice, at the Annual Meeting and prior to commencement of voting, of such stockholder&#146;s
intention to cumulate votes. Otherwise, the proxies solicited by the Board of Directors confer
discretionary authority in the proxy holders to cumulate votes so as to elect the maximum number of
nominees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>How to Vote Your Shares</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>YOUR VOTE IS IMPORTANT</B>. Your shares can be voted at the Annual Meeting only if you are present in
person or represented by proxy. Whether or not you expect to attend the Annual Meeting, please take
the time to vote your proxy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Stockholders of record, or &#147;registered stockholders,&#148; can vote by proxy in the following three
ways:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="70%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By Telephone</B>:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Call the toll-free number indicated on the enclosed
proxy and follow the recorded instructions.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By Internet</B>:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Go to the website indicated on the enclosed proxy and
follow the instructions provided.</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>By Mail</B>:
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mark your vote, date, sign and return the enclosed proxy in
the postage-paid return envelope provided.</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If your shares are held beneficially in &#147;street&#148; name through a nominee such as a brokerage firm,
financial institution or other holder of record, your vote is controlled by that firm, institution
or holder. Your vote by proxy may also be cast by telephone or Internet, as well as by mail, if
your brokerage firm or financial institution offers such voting alternatives. Please follow the
specific instructions provided by your nominee on your voting instruction card.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Even if you have given your proxy, you still may vote in person if you attend the Annual Meeting.
Please note, however, that if your shares are held beneficially through a broker, bank or other
nominee and you wish to vote at the Annual Meeting, you must obtain a proxy issued in your name
from the record holder. Directions to the Sheraton Seattle Hotel can be found on the Company&#146;s
website at http://ir.oncogenex.com/.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Voting of Proxies</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">All shares represented by a valid proxy received prior to the Annual Meeting will be voted, and, if
you provide specific instructions, your shares will be voted as you instruct. If you sign your
proxy card with no further instructions, your shares will be voted FOR each of the nominees for the
Board of Directors, FOR the ratification of Ernst &#038; Young LLP as our independent auditors for the
fiscal year ending December&nbsp;31, 2009, and in the discretion of the proxy holders with respect to
any other matters that properly come before the Annual Meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Revocability of Proxies</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">You may revoke or change a previously delivered proxy at any time before the Annual Meeting by
delivering a written notice of revocation or another proxy with a later date to our Corporate
Secretary at our headquarters at 1522 217th Place S.E. Suite&nbsp;100 Bothell, Washington 98021. You
may also revoke your proxy by attending the Annual Meeting and voting in person, although
attendance at the Annual Meeting will not, by itself, revoke a proxy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Votes Required to Approve Matters Presented at the Annual Meeting</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our directors are elected by a plurality of the votes or shares of common stock present at the
Annual Meeting, either in person or by proxy. Ratification of the selection of Ernst &#038; Young LLP as
our independent auditors requires the affirmative vote of the holders of a majority of the
outstanding shares of common stock present at the Annual Meeting either in person or by proxy and
entitled to vote on the subject matter of the proposal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">A broker non-vote occurs when a nominee holding shares for a beneficial owner does not vote the
shares on a proposal because the nominee does not have discretionary voting power with respect to
that item and has not received instructions from the beneficial owner regarding voting. In these
cases, the nominee can register the shares as being present at the meeting for determining whether
a quorum is present, but will not be able to vote on those matters for which specific authorization
is required. Broker non-votes are not counted or deemed to be present or represented for the
purposes of determining whether stockholders have approved a proposal. Broker non-votes will have
no effect on the outcomes of the votes on the specific matters that are on the Company&#146;s agenda to
be presented at the Annual Meeting. Abstentions are also counted as shares present and entitled to
vote. However, unlike broker non-votes, abstentions have the effect of votes against the proposals
to which they relate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Quorum</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The presence, in person or by proxy, of at least a majority of the shares outstanding on the record
date will constitute a quorum. Both abstentions and broker non-votes are counted for the purpose of
determining the presence of a quorum.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Solicitation of Proxies</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Company will bear the cost of solicitation of proxies, including preparation, assembly,
printing and mailing of this Proxy Statement, the proxy card and any additional information
furnished to stockholders. Copies of solicitation materials will be furnished to banks, brokerage
houses, fiduciaries and custodians holding in their names shares of common stock beneficially owned
by others to forward to such beneficial owners. We may reimburse persons representing beneficial
owners of common stock for their costs of forwarding solicitation materials to such beneficial
owners. Original solicitation of proxies by mail may be supplemented by telephone, telegram,
Internet or personal solicitation by our directors, officers or other regular employees. No
additional compensation will be paid to these individuals for such services.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Availability of Proxy Statement and Annual Report on Form&nbsp;10-K</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our Proxy Statement and Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2008 are
available at <U>www.sec.gov</U> and on our website at <U>http://ir.oncogenex.com/financials.cfm</U>. We have
provided herewith, to each stockholder of record as of March&nbsp;31, 2009, a copy of our consolidated
financial statements and related information included with our Annual Report on Form 10-K for
fiscal year 2008. We will mail without charge, upon written request, a copy of our Annual Report on
Form 10-K for fiscal year 2008, including the consolidated financial statements, schedules and list
of exhibits, and any particular exhibit specifically requested. Requests should be sent to:
OncoGenex Pharmaceuticals, Inc., 1522 217th Place S.E. Suite&nbsp;100, Bothell, Washington 98021,
Attention: Investor Relations.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Arrangement Between Sonus and OncoGenex Technologies</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">On August&nbsp;21, 2008, Sonus Pharmaceuticals, Inc. (&#147;Sonus&#148;) completed its acquisition (the
&#147;Arrangement&#148;) of OncoGenex Technologies Inc. (&#147;OncoGenex Technologies&#148;), a Canadian corporation,
contemplated by the arrangement agreement between Sonus and OncoGenex Technologies dated May&nbsp;27,
2008. In connection with the Arrangement, Sonus changed its name to OncoGenex Pharmaceuticals, Inc.
The term &#147;Sonus&#148; is used herein to refer to the Company prior to the Arrangement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Pursuant to the Arrangement, the Company issued approximately 3,449,393 post-split shares, after
accounting for the elimination of resulting fractional shares, to the former shareholders and
debentureholders of OncoGenex Technologies in exchange for all of the issued and outstanding shares
and debentures of OncoGenex Technologies, and OncoGenex Technologies became a wholly-owned
subsidiary of the Company. Immediately following the Arrangement, the former shareholders and
debentureholders of OncoGenex Technologies beneficially owned approximately 62.6% of the Company&#146;s
shares. For information regarding the current holdings of our directors, executive officers and
major shareholders, see &#147;Security Ownership of Certain Beneficial Owners and Management&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Pursuant to the terms of the arrangement agreement, we reconstituted our Board of Directors on
August&nbsp;21, 2008 to consist of three of the former directors of Sonus, Dwight Winstead, Michelle
Burris and Michael Martino, and three persons designated by OncoGenex Technologies, Scott Cormack,
Neil Clendeninn and Patrick Brady. We also appointed new executive officers, Scott Cormack, Stephen
Anderson and Cindy Jacobs. Matters related to our Board of Directors and executive officers are
described in more detail under the sections below entitled &#147;Board of Directors&#148; and &#147;Executive
Compensation.&#148;
</DIV>
<DIV align="left">
<A name="102"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>BOARD OF DIRECTORS</B>
</DIV>

<DIV align="left">
<A name="103"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>General</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Directors are elected at each annual stockholders meeting to hold office until the next annual
meeting or until their successors are elected and have qualified. Currently, there are six members
of the Board of Directors. The following table sets forth certain information with respect to our
current directors. The ages of such persons are shown as of December&nbsp;31, 2008.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Name and Municipality</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>of Residence</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Age</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Position with the Company</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Director Since</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Scott Cormack<br>
Richmond, Canada</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">44</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director, President and Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2008</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Michael A. Martino<br>Woodinville, Washington</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">53</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director, Member of the Nominating and Governance Committee</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">1998</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Michelle G. Burris<br>Sammamish, Washington</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">43</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director, Chairperson of the Audit Committee and Member of the Compensation Committee <SUP style="font-size: 85%; vertical-align: text-top"><B>(1)</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2004</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Dwight Winstead<br>San Diego, California</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">60</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director, Chairman of the Compensation Committee and Member of the Audit Committee <SUP style="font-size: 85%; vertical-align: text-top"><B>(1)</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">1995</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Neil Clendeninn<br>Hanalei, Hawaii</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">58</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director, Member of the Compensation and Nominating and Governance Committees</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2008</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Patrick R. Brady<br>Vancouver, Canada</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">48</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Director, Member of the Audit and Chairperson of the Nominating and Governance Committees</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">2008</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><SUP style="font-size: 85%; vertical-align: text-top"><B>(1)</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD>Michelle G. Burris and Dwight Winstead also served on the Nominating and Governance
Committee during 2008, and each continued such service until the Nominating and Governance
Committee was reconstituted in March&nbsp;2009.</TD>
</TR>

</TABLE>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">During 2008, until their respective resignations on August&nbsp;21, 2008 in connection with the
Arrangement, George W. Dunbar, Jr. and Robert E. Ivy also served on our Board of Directors. In
addition, Mr.&nbsp;Dunbar served on our Compensation Committee, Nominating and Governance Committee and
Audit Committee, and Mr.&nbsp;Ivy served on our Nominating and Governance Committee and Audit Committee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Board of Directors held a total of 14 meetings during fiscal year 2008. During fiscal year
2008, each of our incumbent directors attended at least 75% of the aggregate of: (i)&nbsp;the total
number of meetings of the Board of Directors held during the period he or she was a director; and
(ii)&nbsp;the total number of meetings held by all committees on which the director served during the
period he or she was a member.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Although we do not have a formal policy regarding attendance by members of the Board of Directors
at annual meetings of stockholders, we encourage directors to attend, and historically, most have
done so. All directors serving at the time of the 2008 annual meeting were in attendance.
</DIV>
<DIV align="left">
<A name="104"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Director Independence</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our Board of Directors has determined that each of our current directors, other than Mr.&nbsp;Martino
and Mr.&nbsp;Cormack, are &#147;independent&#148; under the applicable Securities and Exchange Commission (&#147;SEC&#148;)
rules and the criteria established by the NASDAQ Capital Market (&#147;NASDAQ&#148;). In addition, prior to
their respective resignations from the Board of Directors effective August&nbsp;21, 2008, George W.
Dunbar, Jr. and Robert E. Ivy were also determined to be &#147;independent&#148; under the foregoing
standards.
</DIV>
<DIV align="left">
<A name="105"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Relationships Among Directors, Executive Officers and Director Nominees</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">There are no family relationships between any director, executive officer or director nominee.
</DIV>
<DIV align="left">
<A name="106"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Stockholder Communication with the Board</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Stockholders who are interested in communicating directly with members of the Board of Directors,
or the Board of Directors as a group, may do so by writing directly to the member(s) c/o Secretary,
OncoGenex Pharmaceuticals Inc., 1522 217th Place S.E. Suite&nbsp;100, Bothell, Washington 98021. The
Secretary will promptly forward to the Board of Directors or the individually named directors all
written communications received at the above address.
</DIV>
<DIV align="left">
<A name="107"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Related Party Transactions Policy and Procedure</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our Audit Committee is responsible for reviewing and approving all related party transactions and
conflict of interest situations involving a principal stockholder, a member of the Board of
Directors or senior management. Our Code of Conduct and Business Ethics requires our executive
officers and directors to report any conflicts of interest with the interests of the Company to our
Audit Committee, and generally prohibits our executive officers and directors from conflicts of
interest with the interests of the Company. Waivers of our Code of Conduct and Business Ethics with
respect to an executive officer or director may only be granted by the Board of Directors or, if
permitted by NASDAQ and any other applicable stock exchange&#146;s rules, our Nominating and Governance
Committee. The Company does not have a specific policy concerning approval of transactions with
stockholders who own more than five percent of our outstanding shares.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We have determined that there were no reportable related party transactions to disclose in fiscal
year 2008.
</DIV>
<DIV align="left">
<A name="108"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Board Committees</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Board of Directors has established various separately-designated standing committees to assist
it with the performance of its responsibilities. The Board of Directors designates the members of
these committees and the committee chairs annually, based on the recommendations of the Nominating
and Governance Committee. The Board of Directors has adopted written charters for each of these
committees which are available on our website at http://ir.oncogenex.com under &#147;Corporate
Governance.&#148; The chair of each committee develops the agenda for that committee and determines the
frequency and length of committee meetings.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our Board of Directors has established the following three committees: (1)&nbsp;Audit Committee, (2)
Compensation Committee and (3)&nbsp;Nominating and Governance Committee.
</DIV>
<DIV align="left">
<A name="109"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Audit Committee and Audit Committee Financial Expert</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Board of Directors of the Company has a standing Audit Committee (the &#147;Audit Committee&#148;)
established in accordance with section 3(a)(58)(A) of the Securities Exchange Act of 1934, as
amended (&#147;Exchange Act&#148;), comprised of Michelle G. Burris (Chairperson), Patrick Brady and Dwight
Winstead, each of whom the Board of Directors has determined satisfies the applicable SEC and
NASDAQ independence requirements for audit committee members. In addition, prior to their
respective resignations on August&nbsp;21, 2008, George W. Dunbar and Robert E. Ivy served on the Audit
Committee, and each satisfied the foregoing standards. The Board of Directors has also determined
that Michelle G. Burris is an &#147;audit committee financial expert,&#148; as defined by the applicable
rules of the SEC. The Audit Committee held five meetings during fiscal year 2008.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left">
<A name="110"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Audit Committee Responsibilities</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Audit Committee is responsible for, among other things:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reviewing the independence, qualifications, services, fees, and performance of the
independent auditors;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>appointing, replacing and discharging the independent auditors;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>pre-approving the professional services provided by the independent auditors;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reviewing the scope of the annual audit and reports and recommendations submitted by the
independent auditors; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reviewing the Company&#146;s financial reporting and accounting policies, including any
significant changes, with management and the independent auditors.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">A more detailed description of the Audit Committee&#146;s functions can be found in our Audit Committee
charter at http://ir.oncogenex.com/governance.cfm or by writing to us at 1522 217<SUP style="font-size: 85%; vertical-align: text-top">th</SUP>
Place, S.E. Suite&nbsp;100, Bothell, Washington 98021, Attention: Investor Relations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Please see the sections entitled &#147;Report of the Audit Committee&#148; and &#147;Proposal Two: Ratification of
Appointment of Independent Auditors&#148; for further matters related to the Audit Committee.
</DIV>
<DIV align="left">
<A name="111"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Compensation Committee</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Compensation Committee currently consists of Dwight Winstead (Chairperson), Neil Clendeninn,
and Michelle G. Burris, each of whom the Board of Directors has determined satisfy the applicable
SEC and NASDAQ independence requirements. In addition, prior to his resignation on August&nbsp;21, 2008,
George W. Dunbar also served on the Compensation Committee and satisfied the foregoing standards.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Compensation Committee reviews and recommends to the Board of Directors the compensation for
our executive officers and our non-employee directors for their services as members of the Board of
Directors. The Compensation Committee held four meetings during fiscal year 2008. Each member of
the Compensation Committee is an outside director under Section 162(m) (&#147;Section&nbsp;162(m)&#148;) of the
Internal Revenue Code of 1986, as amended (the &#147;Code&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As discussed in the Compensation Discussion and Analysis, in 2008, the compensation review process
was a wholly internal process. Please see the sections entitled &#147;Compensation Discussion and
Analysis&#148;, &#147;Compensation Committee Report&#148; and &#147;Director Compensation&#148; for further matters related
to the Compensation Committee and executive officer compensation matters.
</DIV>
<DIV align="left">
<A name="112"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Nominating and Governance Committee</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Among other things, the Nominating and Governance Committee reviews, evaluates and proposes
candidates for election to our Board of Directors, and considers any nominees properly recommended
by stockholders. The Nominating and Governance Committee promotes the proper constitution of our
Board of Directors in order to meet its fiduciary obligations to our stockholders, and oversees our
establishment of and compliance with appropriate governance standards. The Nominating and
Governance Committee currently consists of Patrick R. Brady (Chairperson), Neil Clendeninn and
Michael Martino. Michelle G. Burris and Dwight Winstead also served on the Nominating and
Governance Committee during 2008, and each continued such service until the Nominating and
Governance Committee was reconstituted in March&nbsp;2009. Additionally, prior to their respective
resignations on August&nbsp;21, 2008, George W. Dunbar and Robert E. Ivy served on the Nominating and
Governance Committee. The Board of Directors has determined that each of the foregoing current and
former members, other than Mr.&nbsp;Martino, satisfy or satisfied, as applicable, the SEC and NASDAQ
independence requirements. Mr.&nbsp;Martino was appointed to the Nominating and Governance Committee
pursuant to a NASDAQ provision that permits the appointment of one non-independent member to the
Nominating and Governance Committee if the Board of Directors determines that such appointment is
required by the best interests of the Company and its stockholders. Immediately prior to appointing
Mr.&nbsp;Martino to the Nominating and Governance Committee, the Board of Directors determined that his
appointment was required by the best interests of the Company and its stockholders as a result of
Mr.&nbsp;Martino&#146;s familiarity with the Company&#146;s corporate governance policies and the value of
continuity to the Company and its stockholders. The Board of Directors also amended the terms of
the Nominating and Governance Committee Charter to expressly permit the appointment of one
non-independent member, where permitted by NASDAQ and applicable law. The Nominating and Governance
Committee held two meetings during fiscal year 2008.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left">
<A name="113"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Director Nomination Process</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Director Qualifications</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Members of our Board of Directors must have broad experience and business acumen, a record of
professional accomplishment in his or her field, and demonstrated honesty and integrity consistent
with the Company&#146;s values. In evaluating director nominees, the Nominating and Governance Committee
considers a variety of factors, including, without limitation, the appropriate size of the Board of
Directors, the Company&#146;s needs with respect to the particular talents and experience of the
directors, the nominee&#146;s experience and understanding of the pharmaceutical industry, the nominee&#146;s
availability to attend Board of Directors and committee meetings, familiarity with national and
international business matters, experience with accounting rules and practices, and professional
expertise and experience beneficial to the achievement of the Company&#146;s strategic goals. The
Nominating and Governance Committee may also consider such other factors as it may deem are in the
best interests of the Company and its stockholders. Additionally, in accordance with the applicable
securities laws and NASDAQ requirements, a majority of the members of the Board of Directors must
be &#147;independent&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Identification of Nominees By the Board of Directors</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Nominating and Governance Committee identifies nominees by first identifying the desired skills
and experience of a new nominee based on the qualifications discussed above. The Nominating and
Governance Committee will solicit ideas for possible candidates from members of the Board of
Directors, senior level executives and individuals personally known to the members of the Board of
Directors, as well as third-party search firms. The Nominating and Governance Committee evaluates
all possible candidates, including individuals recommended by stockholders, using the same
criteria.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In March&nbsp;2009, the Company engaged Kazan International, an executive search firm specializing in
the life sciences industry, to identify potential director candidates. None of this year&#146;s nominees
for election to the Board of Directors were identified by Kazan International. No fees have been
paid to Kazan International to date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Stockholder Nominations</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our bylaws contain provisions that address the process by which a stockholder may nominate an
individual to stand for election to the Board of Directors. The Nominating and Governance Committee
considers nominees properly recommended by stockholders. Stockholders wishing to submit nominations
must provide timely written notice to our Corporate Secretary containing the following information:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the name and address of the stockholder proposing such business (each such stockholder,
a &#147;Nominating Person&#148;);</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the class and number of shares of the Company that are owned beneficially by each
Nominating Person;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>with respect to each director nominee proposed by a stockholder, such nominee&#146;s written
consent to being named in the Company&#146;s Proxy Statement as a nominee and to serving as a
director, if elected;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>as to each person, if any, whom the Nominating Person proposes to nominate for election
as a director: the name, age, business address and residence address of such person, the
principal occupation or employment of such person and the class and number of shares of the
Company that are beneficially owned by such person; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>such other information regarding each Nominating Person and each nominee proposed by the
Nominating Person as would be required to be disclosed in a proxy statement or other
filings required to be made in connection with the solicitations or proxies for election of
directors, or would be otherwise required, in each case pursuant to Regulation&nbsp;14A under
the Exchange Act and the rules and regulations promulgated thereunder.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">To be timely, a stockholder&#146;s notice in respect of a director nomination must be delivered to or
mailed and received by our Corporate Secretary at our principal executive offices, OncoGenex
Pharmaceuticals, Inc., 1522 217th Place S.E. Suite&nbsp;100, Bothell, Washington 98021, not less than 45
calendar days nor more than 90 calendar days prior to the meeting. However, in the event that less
than 55 calendar days&#146; notice or prior public disclosure of the date of the meeting is given or
made to stockholders, notice by the stockholder to be timely must be received not later than the
close of business on the 10th day following the date on which such notice of the date of the
meeting was mailed or such public disclosure was made.
</DIV>
<DIV align="left">
<A name="114"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Code of Ethics</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We believe that sound corporate governance policies are essential to earning and retaining the
trust of investors. We are committed to maintaining the highest standards of integrity. The Company
has adopted a code of ethics that is applicable to its principal executive officer and principal
financial and accounting officer, as well as to all other employees of the Company, and has posted
such code on the Company&#146;s website at http://ir.oncogenex.com/governance.cfm.
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<DIV align="left">
<A name="115"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>PROPOSAL ONE:<BR>
ELECTION OF DIRECTORS</B>
</DIV>

<DIV align="left">
<A name="116"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Nominees</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">There are six nominees for election to our Board of Directors this year. Unless otherwise
instructed, the proxy holders will vote the proxies received by them for the nominees named below.
If a nominee is unable or declines to serve as a director at the time of the Annual Meeting, the
proxies will be voted for any nominee who is designated by the present Board of Directors to fill
the vacancy. We do not expect that any nominee will be unable or decline to serve as a director.
Each director is elected annually to serve until the next annual meeting of stockholders or until a
successor has been duly elected and qualified. During fiscal year 2008, the following individuals
served on our Board of Directors: Patrick R. Brady, Neil Clendeninn, Michelle G. Burris, Dwight
Winstead, Scott Cormack, and Michael Martino. In addition, George W. Dunbar, Jr. and Robert E. Ivy
served on our Board of Directors until their respective resignations in August&nbsp;2008.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Set forth below are the names of, and certain information concerning, the current director
nominees, each of whom the Nominating and Governance Committee recommended to the Board of
Directors for nomination and the Board of Directors approved for nomination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Scott Cormack</I>, 44, has been President, Chief Executive Officer and Director of the Company since
August&nbsp;21, 2008. He was a co-founder of OncoGenex Technologies, with respect to which he has been
President since May&nbsp;2000, Chief Executive Officer since February&nbsp;2002 and a member of its Board of
Directors since May&nbsp;2000. Mr.&nbsp;Cormack served as interim President, CEO and Chairman of the Board of
Salpep Biotechnology Inc., an asthma and inflammation biotechnology company, from 2000 to 2001.
From 1998 to 2001, Mr.&nbsp;Cormack served as Vice President of Milestone Medica Corporation, a seed
venture capital firm investing in life sciences opportunities. From 1995 to 1998, Mr.&nbsp;Cormack
served as Chief Operating Officer of NeuroSpheres Ltd, a neural stem cell biotechnology company.
Mr.&nbsp;Cormack was President and founder of For Tomorrow, a sole proprietorship engaged in business
consulting, from 1991 to 1999. From 1986 to 1988, Mr.&nbsp;Cormack served as Territory Manager of
Vetrepharm Inc. (now Bioniche Life Sciences, Inc.), a biopharmaceutical company developing products
for human and animal health markets, and from 1988 to 1991 served as Technology Manager,
Immunomodulators of Vetrepharm Inc. From October&nbsp;2005 to October&nbsp;2008, Mr.&nbsp;Cormack has served as
Director of Life Sciences British Columbia. Mr.&nbsp;Cormack holds a Bachelor of Science degree from the
University of Alberta.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Michelle G. Burris</I>, 43, has been a director of the Company since May&nbsp;2004. Ms.&nbsp;Burris is currently
Senior Vice President and Chief Financial Officer of Trubion Pharmaceuticals, Inc, a position she
has held since February&nbsp;2006. From August&nbsp;2005 to January&nbsp;2006, Ms.&nbsp;Burris served as Senior Vice
President and Chief Financial Officer at Dendreon Corporation. From January&nbsp;2001 to July&nbsp;2005, she
served as Senior Vice President and Chief Financial Officer at Corixa Corporation, which was sold
to GlaxoSmithKline in 2005. Ms.&nbsp;Burris had worked at Corixa since its inception in 1994, and prior
to her last position at the firm, had served in various capacities of increasing responsibility in
finance and operations. Prior to Corixa, Ms.&nbsp;Burris held several finance and strategic planning
positions at The Boeing Company. Ms.&nbsp;Burris is on the Advisory Board of Albers School of Business
and Economics at Seattle University. She received a Post Graduate Certificate in accounting and an
MBA from Seattle University, and a B.S. from George Mason University. Ms.&nbsp;Burris received her
Certified Public Accountant Certification from the State of Washington; however, she is no longer
an active CPA.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Dwight Winstead, </I>60, has served as a director of the Company since July&nbsp;1995. Mr.&nbsp;Winstead is
currently Chief Operating Officer of Cardinal Health Clinical and Medical Products (CMP), a
subsidiary of Cardinal Health, Inc. Prior to his current position at CMP, he served as Group
President of Cardinal Health Clinical Technologies and Services, (CTS), Group President of Clinical
Services and Consulting and President of Pyxis Products, formerly known as AIS (Automated
Information Services) since 1997. From 1991 to 1997, Mr.&nbsp;Winstead served as Executive Vice
President of VHA, Inc., a performance improvement company serving health care organizations in the
United States. Prior to his promotion to Executive Vice President, Mr.&nbsp;Winstead served in various
capacities of VHA Supply Company, a subsidiary of VHA, Inc., including Vice President, Sales and
Marketing, Senior Vice President, Chief Operating Officer and President from 1987 to 1991. Prior to
joining VHA, Inc. in 1984, Mr.&nbsp;Winstead served in a variety of materials management and sales
positions in several companies, including Ortho Instruments and Worthington Diagnostics. Mr.
Winstead holds a B.S. from Delta State University.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Neil Clendeninn</I>, M.D., Ph.D., 58, has served as a director of the Company since August&nbsp;21, 2008.
Additionally, he has served as a member of OncoGenex Technologies&#146; Board of Directors since
September&nbsp;2004. Dr.&nbsp;Clendeninn served as Corporate Vice President, Head of Clinical Affairs of
Agouron Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., from 1993 until his retirement in 2001.
Dr.&nbsp;Clendeninn holds a B.A. Biology/Chemistry from Wesleyan University, and a Ph.D.
Microbiology/Pharmacology and M.D. from New York University.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Patrick R. Brady</I>, 49, has served as a director of the Company since August&nbsp;21, 2008. He is Vice
President, Investments at GrowthWorks Capital Ltd., a venture capital fund management firm based in
Vancouver, British Columbia, Canada. GrowthWorks
managed funds, including the Working Opportunity Fund and GrowthWorks Canadian Fund, have a
combined $750&nbsp;million in assets. Mr.&nbsp;Brady serves as either a member of the Board or an observer
for Celator Technologies, Inimex Pharmaceuticals, MSI Methylation Sciences, Inc., Neuromed
Pharmaceuticals, OncoGenex Technologies, Twinstrand Therapeutics and Xenon Genetics. Prior to
joining GrowthWorks in 1998, Mr.&nbsp;Brady worked at Inex Pharmaceuticals and DynaMotive Technologies
Corp. in financial and corporate development capacities. Mr.&nbsp;Brady holds an MBA from the University
of Western Ontario and was a former professional athlete. He is a past director of the BC Biotech
Association.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Michael A. Martino</I>, 53, has been a director of the Company since September&nbsp;1998. Additionally, in
September&nbsp;1998, he was appointed President and Chief Operating Officer of the Company and was
appointed Chief Executive Officer of the Company in July&nbsp;1999. In connection with the Arrangement,
Mr.&nbsp;Martino resigned his officer positions with the Company effective August&nbsp;21, 2008. From 1983 to
1998, Mr.&nbsp;Martino held numerous positions of increasing responsibility in strategic planning,
business development, marketing and sales, and general management with Mallinckrodt, Inc., a global
healthcare products company, including serving as Vice President and General Manager of the Nuclear
Medicine Division. Mr.&nbsp;Martino holds a B.A. in business from Roanoke College and an M.B.A. from
Virginia Tech. He sits on the Presidents Advisory Board of Roanoke College and is a member of the
Board of Trustees of Cascadia Community College. In addition, Mr.&nbsp;Martino is a past Chairman of the
Board of the Washington Biotechnology and Biomedical Association (WBBA).
</DIV>
<DIV align="left">
<A name="117"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Director Compensation Overview</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our Nominating and Governance Committee charter and our Compensation Committee charter provide that
the Nominating and Governance Committee and the Compensation Committee, respectively, are to
recommend to the Board of Directors matters related to director compensation. The director
compensation package for non-employee directors consists of annual cash compensation and an award
of stock options exercisable to purchase shares of common stock of the Company. No additional
compensation is paid to any director for serving on any committee of the Board of Directors, for
being the Chair of any committee or for attending meetings. In addition, no employee of the Company
shall be entitled to compensation for service as a director. The compensation paid during 2008 is
as set forth in the table below under the heading &#147;Director Compensation Paid for 2008.&#148; The
Company&#146;s new director compensation policy adopted in 2009 is as set forth below under the heading
&#147;Current Director Compensation&#148;. Prior to March&nbsp;2009, the award of stock options was determined by
the Compensation Committee, as the administrator of the applicable stock option plans of the
Corporation. In March&nbsp;2009, the Board of Directors became the administrator of each of the
Company&#146;s various equity compensation plans.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">At least every two years or upon direction of the Compensation Committee, management reviews peer
group data to determine whether total direct compensation, and each component of the compensation
package, are approximately equal to the targeted fiftieth percentile for director compensation of
the Company&#146;s peer company list. Based on such review, management makes any recommendations to the
Nominating and Governance Committee deemed necessary to align the director compensation with the
foregoing peer group target. Up to October&nbsp;28, 2008, the peer group list was comprised of the
following companies:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">Allos Therapeutics<br>
ARIAD Pharmaceuticals<br>
BioCryst Pharmaceuticals<br>
Cell Genesys <br>
Cell Therapeutics <br>
Columbia Laboratories <br>
Dendreon <br>
DepoMed <br>
Emisphere Technologies <br>
Enzon Pharmaceuticals <br>
ImmunoGen <br>
Inovio Biomedical<br>
Introgen Therapeutics<br>
Nastech Pharmaceuticals<br>
Novacea<br>
NovaDel Pharma<br>
Noven Pharmaceuticals<br>
Penwest Pharmaceuticals<br>
Peregrine Pharmaceuticals<br>
Seattle Genetics<br>
SuperGen<br>
Trubion
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Upon the request of the Compensation Committee and in consideration of the Company&#146;s change in
market capitalization and number of employees, management reviewed our peer group used for setting
2009 compensation. The revised peer group list used for setting 2009 compensation was comprised of
the following companies which were deemed to be comparable based on the Company&#146;s market
capitalization and number of employees:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">Cell Genesys<br>
Cell Therapeutics<br>
Emisphere Technologies<br>
Introgen Therapeutics<br>
Novacea<br>
Penwest Pharmaceuticals<br>
Peregrine Pharmaceuticals<br>
SuperGen<br>
Trubion<br>
Avalon<br>
Curagen<br>
Cyclacel<br>
Entremed<br>
Sunesis<br>
Ziopharm
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The peer group companies are amended from time to time at the discretion of the Board of Directors.
</DIV>
<DIV align="left">
<A name="118"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Current Director Compensation Policy</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In March&nbsp;2009, the Board of Directors established the compensation for non-employee directors in
connection with their service on the Board of Directors and its committees, as follows:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>An annual retainer of $65,000 will be paid quarterly to each non-employee Chair or lead
director of the Board of Directors, if any, and an annual retainer of $44,000 will be paid
quarterly for all other non-employee directors. The annual cash compensation will be paid in
four quarterly installments, with such payments being paid in arrears of director services
provided and within ten days following the completion of the calendar quarter. Each quarterly
payment is conditioned upon the director remaining a director of the Company on the date of
the payment.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Directors will be reimbursed for certain expenses incurred for meetings of the Board of
Directors (or its committees) attended.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For a newly appointed or elected director, an initial stock option grant will be awarded
such that the number of shares of common stock subject thereto shall be equal to the number
that results in the award having a Value (defined below) of $55,000, subject to a maximum of
20,000 Shares. Each initial stock option grant shall vest quarterly over three years.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>For a director re-elected by the stockholders of the Company at the annual meeting, an
annual stock option grant will be awarded such that the number of shares of common stock
subject thereto shall be that number that results in the award having a Value (defined below)
of $34,000, subject to a maximum of 17,000 Shares. In the case of a director that was
appointed or elected to the Board of Directors for the first time as of a date subsequent to
December&nbsp;31, 2008, and who has received an initial grant, such director&#146;s first annual grant
will be reduced by multiplying the number of shares that would otherwise be subject to such
annual grant by the fraction of a year during which the director served on the Board of
Directors immediately preceding the date of the annual meeting. Each annual stock option grant
shall vest quarterly over one year.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">&#147;Value&#148;, as used above, is defined as the value derived from the Black Scholes formula, using the
following additional inputs: (i)&nbsp;expected life of four years; (ii)&nbsp;annualized volatility as at the
date of grant, as determined by the Board; (iii)&nbsp;a dividend yield of 0%; and (iv)&nbsp;a risk free
interest rate of the midpoint between the three and five year T-bill rates in effect at the date of
grant, regardless of the expense recognized by the Company for financial statement purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Company does not currently have a Chair or lead director of the Board of Directors.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left">
<A name="119"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Director Compensation Paid for 2008</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following table summarizes all compensation paid to or earned by our non-employee directors for
fulfilling their duties as directors of the Company during the 2008 fiscal year.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="58%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Fees Earned</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>or Paid in</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Option</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Cash</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Awards</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Total</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B><SUP style="font-size: 85%; vertical-align: text-top"><B>(1)</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Patrick Brady</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">15,968</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,543</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,511</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Michelle G. Burris</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">44,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,543</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">48,543</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Neil Clendeninn</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">15,968</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,543</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,511</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Michael Martino<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">15,968</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,543</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">20,511</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dwight Winstead</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">44,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">4,543</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">48,543</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">George W. Dunbar, Jr.<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,978</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,978</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Robert E. Ivy<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,978</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">27,978</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<DIV align="left"><DIV style="font-size: 10pt; margin-top: 10pt; width: 18%; border-bottom: 1px solid #000000">&nbsp;</DIV></DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>This column reflects the dollar amount recognized for financial statement reporting purposes
in accordance with FAS 123(R) and thus includes amounts from awards granted prior to the
current fiscal year. Assumptions used in the calculation of the amounts in this column are
included in footnote 12 to the Company&#146;s audited financial statements included in our 2008
Annual Report on Form 10-K. These options were granted on October&nbsp;28, 2008, in part under the
1999 Nonqualified Stock Incentive Plan and in part under the 2000 Stock Incentive Plan and
vest quarterly over one year. Each respective director&#146;s options had a grant date fair value
of $1.53 computed in accordance with FAS 123R. As of December&nbsp;31, 2008, the following
directors had the following number of options outstanding:</TD>
</TR>

</TABLE>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Patrick Brady: 17,000, of which nil were vested as of 12/31/08. 4,250 option vest
on each of January&nbsp;28, 2009, April&nbsp;28, 2009, July&nbsp;28, 2009 and October&nbsp;28, 2009;</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dwight Winstead: 17,000, of which nil were vested as of 12/31/08. 4,250 option
vest on each of January&nbsp;28, 2009, April&nbsp;28, 2009, July&nbsp;28, 2009 and October&nbsp;28,
2009;</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Michelle G. Burris: 17,000, of which nil were vested as of 12/31/08. 4,250 option
vest on each of January&nbsp;28, 2009, April&nbsp;28, 2009, July&nbsp;28, 2009 and October&nbsp;28,
2009;</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Neil Clendeninn: 27,610, of which 10,610 were vested as of 12/31/08. 4,250 option
vest on each of January&nbsp;28, 2009, April&nbsp;28, 2009, July&nbsp;28, 2009 and October&nbsp;28,
2009; and</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Michael Martino: 17,000, of which nil were vested as of 12/31/08. 4,250 option
vest on each of January&nbsp;28, 2009, April&nbsp;28, 2009, July&nbsp;28, 2009 and October&nbsp;28,
2009.</TD>
</TR>

</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt; margin-left: 4%">The following directors and former directors, as applicable, forfeited options during 2008:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Michelle G. Burris: 3,277 options at a weighted average exercise price of $91.46;</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>George Dunbar: 7,861 options at a weighted average exercise price of $70.89;</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Robert E. Ivy: 5,785 options at a weighted average exercise price of $83.55; and</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Dwight Winstead: 7,861 options at a weighted average exercise price of $70.89.</TD>
</TR>

</TABLE>
</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>The amounts shown in this table for Michael Martino relate to his services as a non-employee
director of the Company during the time period from August&nbsp;21, 2008 through December&nbsp;31, 2008.
Information related to compensation earned by Mr.&nbsp;Martino in connection with his services as
an executive officer of the Company during the time period from January&nbsp;1, 2008 through August
20, 2008 is included in the Summary Compensation Table contained elsewhere herein.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>In connection with the Arrangement, George W. Dunbar, Jr. and Robert E. Ivy resigned as
directors, effective August&nbsp;21, 2008, and thus, their compensation reported herein pertains to
the time period from January&nbsp;1, 2008 through August&nbsp;20, 2008.</TD>
</TR>

</TABLE>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><FONT style="font-variant: SMALL-CAPS"><B>The Board of Directors unanimously recommends that stockholders vote &#147;FOR&#148; the ELECTION of all
of the nominees.</B></FONT>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left">
<A name="120"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>REPORT OF THE AUDIT COMMITTEE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In connection with the financial statements for the fiscal year ended December&nbsp;31, 2008, the Audit
Committee has:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>reviewed and discussed the audited financial statements with management;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>discussed with Ernst &#038; Young LLP, OncoGenex&#146;s independent registered public accounting firm,
the matters required to be discussed by the statement on Auditing Standards No.&nbsp;61,
Communication with Audit Committees, as amended; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>received the written disclosures and letter from Ernst &#038; Young LLP required by applicable
requirements of the Public Company Accounting Oversight Board regarding the independent
accountant&#146;s communications with the audit committee concerning independence, and has
discussed with Ernst &#038; Young LLP its independence from OncoGenex.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Based on the Audit Committee&#146;s review of the audited consolidated financial statements and its
discussions with management and Ernst &#038; Young LLP, the Audit Committee recommended to the Board of
Directors at the March&nbsp;5, 2009 Board Meeting that the audited consolidated financial statements for
the 2008 fiscal year be included in the Company&#146;s Annual Report on Form 10-K filed with the SEC.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="50%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">AUDIT COMMITTEE OF THE BOARD OF DIRECTORS</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michelle G. Burris</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Patrick R. Brady</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dwight Winstead</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>The information contained in the report above shall not be deemed to be &#147;soliciting material&#148; or to
be &#147;filed&#148; with the Securities and Exchange Commission, nor shall such information be incorporated
by reference into any future filing under the Securities Act of 1933, as amended, or the Exchange
Act, except to the extent specifically incorporated by reference therein.</I></B>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left">
<A name="121"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>PROPOSAL TWO:<BR>
RATIFICATION OF APPOINTMENT OF INDEPENDENT AUDITORS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Audit Committee has appointed Ernst &#038; Young LLP as our independent auditors for the fiscal year
ending December&nbsp;31, 2009. A representative of Ernst &#038; Young LLP will be present at the Annual
Meeting, will be given the opportunity to make a statement, if he or she desires, and will be
available to respond to appropriate questions.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Audit Committee has conditioned its appointment of Ernst &#038; Young LLP as our independent
auditors upon the receipt of an affirmative vote of a majority of the shares of common stock
present in person or represented by proxy and entitled to be voted at the Annual Meeting. In the
event that the stockholders do not ratify the appointment of Ernst &#038; Young LLP, the Audit Committee
will reconsider its selection.
</DIV>
<DIV align="left">
<A name="122"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Principal Accountant for Previous Fiscal Years</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">On August&nbsp;23, 2008, the Audit Committee of the Board of Directors of the Company approved the
engagement of Ernst &#038; Young LLP (Canada) (&#147;E&#038;Y Canada&#148;) as the Company&#146;s independent registered
public accounting firm for the fiscal year ended December&nbsp;31, 2008, with the engagement to be
effective upon receipt by the Company of the resignation of Ernst &#038; Young LLP (US) (&#147;E&#038;Y US&#148;). On
August&nbsp;26, 2008, the Company received the resignation of E&#038;Y US. This change in accountants was
effected solely as a result of the completion of the transactions contemplated by the Arrangement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The report of E&#038;Y US on the consolidated balance sheets of the Company as of December&nbsp;31, 2007 and
2006, and the related statements of operations, stockholders&#146; equity and cash flows for each of the
three years in the period ended December&nbsp;31, 2007, contained no adverse opinion or disclaimer of
opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles.
The audit reports of E&#038;Y US on the effectiveness of internal control over financial reporting as of
December&nbsp;31, 2007 and December&nbsp;31, 2006 did not contain any adverse opinion or disclaimer of
opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting
principles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">During the Company&#146;s two most recent fiscal years and any subsequent interim period prior to the
date of this report, there were no: (a)&nbsp;disagreements between the Company and E&#038;Y US on any matter
of accounting principles or practices, financial statement disclosure or auditing scope or
procedure, which disagreements, if not resolved to the satisfaction of E&#038;Y US, would have caused
E&#038;Y US to make reference to the subject matter of the disagreement in their report on the financial
statements for such years; or (b) &#147;reportable events&#148; as that term is defined in Item&nbsp;304(a)(1)(v)
of Regulation&nbsp;S-K under the Exchange Act (&#147;Regulation&nbsp;S-K&#148;). During the Company&#146;s two most recent
fiscal years and any subsequent interim period prior to the date of this report, the Company did
not consult with E&#038;Y Canada regarding matters or events set forth in Item&nbsp;304(a)(2)(i) or (ii)&nbsp;of
Regulation&nbsp;S-K.
</DIV>
<DIV align="left">
<A name="123"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Fees Billed by Independent Auditors</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following is a summary of the fees billed by the Company&#146;s outside accountant for the fiscal
years ended December&nbsp;31, 2008 and December&nbsp;31, 2007 for professional services rendered to the
Company:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Fiscal 2008</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Fiscal 2007</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Fee Category</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Fees</B><SUP style="font-size: 85%; vertical-align: text-top"><B>(1)</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Fees</B><SUP style="font-size: 85%; vertical-align: text-top"><B>(2)</B></SUP></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Audit Fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">199,379</TD>
    <TD nowrap><SUP style="font-size: 85%; vertical-align: text-top"><B>(3)</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">357,020</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Audit Related Fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">149,214</TD>
    <TD nowrap><SUP style="font-size: 85%; vertical-align: text-top"><B>(4)</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">15,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tax Fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">14,000</TD>
    <TD nowrap><SUP style="font-size: 85%; vertical-align: text-top"><B>(5)</B></SUP></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,910</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">All Other Fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">0</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="2" align="right" style="border-top: 1px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total Fees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">362,593</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">385,930</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
        <TD nowrap colspan="2" align="right" style="border-top: 3px double #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>Accountant fees and services charged by E&#038;Y Canada are paid in Canadian dollars, and thus,
the amounts shown in the column for Fiscal 2008 Fees have been translated into U.S. dollars
based on average exchange rates.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>Accountant fees and services billed prior to August&nbsp;21, 2008 relate to Sonus only. Accountant
fees and serviced billed from August&nbsp;21, 2008 to December&nbsp;31, 2008 relate to OncoGenex
Pharmaceuticals Inc. after the Arrangement.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>Of the $199,379 in Audit Fees paid in 2008, $40,500 was paid to E&#038;Y US and $158,879 was paid
to E&#038;Y Canada.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(4)</TD>
    <TD>&nbsp;</TD>
    <TD>Of the $149,214 in Audit Related Fees paid in 2008, $139,868 was paid to E&#038;Y US and $9,346
was paid to E&#038;Y Canada.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(5)</TD>
    <TD>&nbsp;</TD>
    <TD>$14,000 in tax fees were paid to E&#038;Y US.</TD>
</TR>

</TABLE>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Audit Fees</I></B>. Consists of fees billed for professional services rendered for the audit of the
Company&#146;s financial statements and review of the interim financial statements included in quarterly
reports.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Audit-Related Fees</I></B>. Consists of fees billed for assurance and related services by the principal
accountant that are reasonably related to the performance of the audit or review of the
registrant&#146;s financial statements including accounting consultations and fees related to equity
financings.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>Tax Fees</I></B>. Consists of fees billed for professional services for tax compliance, tax advice and tax
planning. These services include assistance related to state tax incentives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B><I>All Other Fees</I></B>. Consists of fees billed for all other non-audit services.
</DIV>
<DIV align="left">
<A name="124"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Policy on Audit Committee Pre-Approval of Audit Services and Permissible Non-Audit Services</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Audit Committee&#146;s policy is to pre-approve all audit and permissible non-audit services
performed by the independent auditors. These services may include audit services, audit-related
services, tax services and other services. For audit services, the independent auditor typically
provides audit service detail in advance of the first quarter meeting of the Audit Committee,
outlining the scope of the audit and related audit fees. If agreed to by the Audit Committee, an
engagement letter is formally accepted by the Audit Committee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">For non-audit services, the Company&#146;s senior management will submit from time to time to the Audit
Committee for approval non-audit services that it recommends the Audit Committee engage the
independent auditor to provide for the fiscal year. The Company&#146;s senior management and the
independent auditor will each confirm to the Audit Committee that each non-audit service is
permissible under all applicable legal requirements. A budget, estimating non-audit service
spending for the fiscal year, will be provided to the Audit Committee along with the request. The
Audit Committee must approve both permissible non-audit services and the budget for such services.
The Audit Committee will be informed routinely as to the non-audit services actually provided by
the independent auditor pursuant to this pre-approval process.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">For the 2007 and 2008 fiscal years, the Audit Committee approved 100% of the services provided by
Ernst &#038; Young LLP described above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE &#147;FOR&#148; THE RATIFICATION OF THE
APPOINTMENT OF ERNST &#038; YOUNG LLP AS OUR INDEPENDENT AUDITORS FOR FISCAL YEAR 2009.</B>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left">
<A name="125"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following table sets forth certain information with respect to the beneficial ownership of our
common stock of the following persons as of the dates set forth below:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>each person or entity who we know to beneficially own five percent or more of the voting
securities of the Company, as of December&nbsp;31, 2008;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>each director and director nominee, as of April&nbsp;7, 2009;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>each of our named executive officers identified in the Summary Compensation Table below,
as of April&nbsp;7, 2009; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>all of our current directors and executive officers as a group, as of April&nbsp;7, 2009.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Unless otherwise indicated below, the address of each beneficial owner listed in the table is c/o
OncoGenex Pharmaceuticals, Inc., 1522 217th Place S.E., Bothell, Washington 98021. The percentages
in the table below are based on 5,549,905 shares of our common stock outstanding as of April&nbsp;7,
2009. Except as indicated in the footnotes to this table and pursuant to applicable community
property laws, to our knowledge, each stockholder named in the table has sole voting and investment
power with respect to the shares set forth opposite such stockholder&#146;s name. The information
provided in this table is based on our records and information filed with the SEC, unless otherwise
noted.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="38%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Amount and</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Nature of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Name of Beneficial</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Beneficial</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Percent of</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Owner</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Business Address</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Ownership(1)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Class(1)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top" style="background: #cceeff">
    <TD><DIV style="margin-left:0px; text-indent:-0px">H.I.G. Horizon<br>Corporation (2)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">c/o 1001 Brickell Bay Drive, <br>27th Floor <br>Miami, Florida 33131</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">733,912</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">13.2</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="top" style="padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Working Opportunity<br>Fund (EVCC)&nbsp;Ltd. (3)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Box 11170, Royal Centre <br>2600 - 1055 West Georgia Street <br>Vancouver, BC  V6E 3R5</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">517,344</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">9.3</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="top" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Ventures West Capital Ltd. (4)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Suite 400, 999 West Hastings St. <BR>
Vancouver, British Columbia <BR>
Canada V6C 2W2</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">476,819</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8.6</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="top" style="padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">BDC Capital Inc. (5)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Suite 300, 5 Place Ville Marie, <BR>
Montreal, Quebec, <BR>
Canada H3B 5E7</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">319,220</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.8</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="top" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px"><I>Executive Officers and
Directors:</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Scott Cormack (6)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">141,682</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">2.6</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Michael A. Martino (7)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">43,111</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">*</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stephen Anderson (8)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">34,776</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">*</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cindy Jacobs (9)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">27,221</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">*</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Neil Clendeninn (10)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">19,110</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">*</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Michelle G. Burris (11)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8,500</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">*</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Dwight Winstead (11)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8,500</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">*</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Patrick Brady (11) (12)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">8,500</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">*</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">All executive officers
and directors as a
group <BR>
(8 persons)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">291,400</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">5.3</TD>
    <TD nowrap valign="top">%</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">*</TD>
    <TD>&nbsp;</TD>
    <TD>Less than 1%</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>Beneficial ownership is determined in accordance with the rules of the SEC and generally
includes voting or investment power with respect to securities. Shares of common stock subject
to options currently exercisable, or exercisable within 60&nbsp;days of April&nbsp;7, 2009, are deemed
outstanding for computing the percentage of the person holding such options but are not deemed
outstanding for computing the percentage of any other person.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>This information is based solely on a Schedule&nbsp;13G filed on September&nbsp;2, 2008 by H.I.G.
Oncogenex, Inc. The 733,912 common shares are owned directly by H.I.G. Horizon Corporation,
which is a wholly-owned subsidiary of H.I.G. Key Corporation, which is a wholly-owned
subsidiary of H.I.G. Oncogenex, Inc. Sami W. Mnaymneh and Anthony Tamer are the shareholders
of HIG-GP II, Inc., the general partner and managing member, respectively, of the two entities
which are indirectly the majority shareholders of H.I.G. Oncogenex, Inc. H.I.G. Key
Corporation and H.I.G. Oncogenex, Inc. and Messrs.&nbsp;Mnaymneh and Tamer may be deemed to be
indirect beneficial owners of the reported securities, but disclaim beneficial ownership in
the securities, except to the extent of its or his pecuniary interest in the shares.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>The Schedule&nbsp;13D/A filed on February&nbsp;17, 2009 by Working Opportunity Fund (EVCC)&nbsp;Ltd. (&#147;WOF&#148;)
and GrowthWorks Capital Ltd. (collectively, the &#147;Reporting Persons&#148;) reported that such
Reporting Persons are each the beneficial owner of 525,844 shares. The Reporting Persons&#146;
Schedule13D/A also states that &#147;Pat Brady holds options to purchase 17,000 shares of the
Company&#146;s stock, which is held in trust for WOF.&#148; Of these options, only 8,500 are exercisable
within 60&nbsp;days of April&nbsp;7, 2009; thus, the aggregate amount of shares and options exercisable
within 60&nbsp;days of April&nbsp;7, 2009 that are beneficially owned by the Reporting Persons is
actually 517,344. Of the amount of shares reported as beneficially owned by the Reporting
Persons, the Reporting Persons state that they are each the record owner of 508,844 of such
shares. The Reporting Persons further state that, as the investment manager of WOF,
GrowthWorks may be deemed to beneficially own the 508,844 shares of common stock, and that the
Reporting Persons share power to vote and dispose of the shares of common stock. Each of the
Reporting Persons expressly disclaims beneficial ownership of the 508,844 shares, except any
shares in which they have an actual pecuniary interest.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(4)</TD>
    <TD>&nbsp;</TD>
    <TD>This information is based solely on a Schedule&nbsp;13G /A filed on December&nbsp;17, 2008 by Ventures
West Capital Ltd. Of the 476,819 shares of common stock beneficially owned by Ventures West
Capital Ltd., 435,056 shares of common stock are held of record by Ventures West 7 Limited
Partnership, whose general partner is Ventures West 7 Management Ltd, an entity wholly owned
by Ventures West Capital Ltd. and whose officers are similar to the officers of Ventures West
Capital Ltd, and 41,763 shares of common stock are held of record by Ventures West 7 U.S.
Limited Partnership, whose manager is Ventures West 7 Management (International) Inc., an
entity controlled by Ventures West Capital Ltd. and whose officers are similar to the officers
of Ventures West Capital Ltd. All transactions involving securities held by Ventures West 7
Limited Partnership and Ventures West 7 U.S. Limited Partnership are completed in parallel.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(5)</TD>
    <TD>&nbsp;</TD>
    <TD>This information is based solely on a Schedule&nbsp;13G filed on August&nbsp;29, 2008 by BDC Capital
Inc. BDC Capital Inc. is deemed to have beneficial ownership, and sole voting and dispositive
power, over the 319,220 shares of common stock.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(6)</TD>
    <TD>&nbsp;</TD>
    <TD>Consists of 6,306 shares owned directly, 24,809 shares owned indirectly through Trycor
Investment Trust, 1,015 shares owned indirectly through his spouse, 88,212 options owned
directly exercisable within 60&nbsp;days of April&nbsp;10, 2009, and 21,340 options owned indirectly
through his spouse exercisable within 60&nbsp;days of April&nbsp;10, 2009.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(7)</TD>
    <TD>&nbsp;</TD>
    <TD>Consists of 11,000 shares owned directly and 32,111 options exercisable within 60&nbsp;days
April&nbsp;10, 2009.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(8)</TD>
    <TD>&nbsp;</TD>
    <TD>Consists of 11,000 shares owned indirectly through his spouse, 2,000 shares owned indirectly
through his Registered Retirement Savings Plan, and 21,776 options exercisable within 60&nbsp;days
April&nbsp;10, 2009.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(9)</TD>
    <TD>&nbsp;</TD>
    <TD>Consists of 27,221 options exercisable within 60&nbsp;days of April&nbsp;10, 2009.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(10)</TD>
    <TD>&nbsp;</TD>
    <TD>Consists of 19,110 options exercisable within 60&nbsp;days of April&nbsp;10, 2009.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(11)</TD>
    <TD>&nbsp;</TD>
    <TD>Consists of 8,500 options exercisable within 60&nbsp;days of April&nbsp;10, 2009.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(12)</TD>
    <TD>&nbsp;</TD>
    <TD>The Reporting Persons&#146; Schedule13D/A filed on February&nbsp;17, 2009 by the Reporting Persons
states that &#147;Pat Brady holds options to purchase 17,000 shares of the Company&#146;s stock, which
is held in trust for WOF.&#148; Of these options, 8,500 are exercisable within 60&nbsp;days of April&nbsp;7,
2009.</TD>
</TR>

</TABLE>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>
<DIV align="left">
<A name="126"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>COMPENSATION DISCUSSION AND ANALYSIS</B>
</DIV>

<DIV align="left">
<A name="127"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Overview</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As a result of the Arrangement in August&nbsp;2008, we inherited two distinct sets of compensation
policies and programs:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>those policies and programs adopted by OncoGenex Technologies, which had been
established at a time when OncoGenex Technologies was a private Canadian company; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>those policies and programs adopted by Sonus, which had most recently been evaluated at
a time when Sonus had a significantly larger market capitalization and a larger workforce.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Between October&nbsp;2008 and March&nbsp;2009, the Compensation Committee, with the assistance of management
and the Board of Directors, undertook a comprehensive review of our compensation policies and
programs for our executive officers, employees and directors. The factors considered as part of the
Compensation Committee&#146;s review included:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our desire to integrate the compensation policies and programs of the two organizations;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>our industry, geographic profile, market capitalization and workforce;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the existing policies, programs and contractual obligations of Sonus and OncoGenex
Technologies;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>individual and corporate performance; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the market practices reported in the 2008 Radford Global Life Sciences Survey.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Following this review and resulting approvals by the Compensation Committee and the Board of
Directors, our compensation policies and programs and their application to our Named Executive
Officers (defined under the heading &#147;Executive Compensation&#148;) are as described below.
</DIV>
<DIV align="left">
<A name="128"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Compensation Philosophy and Objectives</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We believe that attracting and retaining human talent is a critical element of our ability to
achieve our strategic goals and objectives. The labor markets in which we compete for human talent,
nationally and locally, are very competitive and, to be successful, we believe we have to offer
compensation programs that are competitive with other life science companies, large and small, that
are competing for the same talent. The components of our compensation programs consist of base
salary, annual merit increases, short-term incentive awards and long-term incentive awards, and are
designed to align incentives and rewards for our executives and employees with our overall business
strategies, goals and objectives, and also to take into account our ability to fund these
compensation programs.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">To achieve these objectives we have established compensation plans that tie a substantial portion
of executives&#146; overall compensation to key strategic financial and operational goals such as the
establishment and maintenance of key strategic relationships and the development of our product
candidates. The Compensation Committee&#146;s approach emphasizes the setting of compensation at levels
it believes are competitive with executives in other companies of similar size and stage of
development operating in the biotechnology industry, while taking into account our relative
performance and our own strategic goals. Overall, our pay programs attempt to balance cash and
equity to reward both short- and long-term performance.
</DIV>
<DIV align="left">
<A name="129"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Compensation Review Process and the Role of Executive Officers in Compensation Decisions</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The compensation review process began in the fourth quarter of 2008 with a presentation by
management to the Compensation Committee of a review of current compensation philosophies and
programs amongst the Company and its subsidiaries, which included recommendations to harmonize
their respective philosophies and programs. In November&nbsp;2008, the Chief Executive Officer produced
an executive compensation review for each executive, excluding the Chief Executive Officer, which
included recommendations for 2009 base salary, annual merit increases, short-term incentive plan
compensation and long-term incentive plan. The recommendations of the Chief Executive Officer were
considered by the Compensation Committee. The Compensation Committee evaluated and revised the
Chief Executive Officer&#146;s recommendations and forwarded its own recommendations to our Board of
Directors, which suggested further revisions. The Compensation Committee also held in camera
sessions without the Chief Executive Officer present to discuss the Chief Executive Officer&#146;s
compensation and make recommendations regarding the same to our Board of Directors. Our Board of
Directors considered the Compensation Committee&#146;s recommendations with respect to the Chief
Executive Officer in an in camera session and provided feedback to the Compensation Committee. In
December&nbsp;2008, the Compensation Committee then approved for each executive officer such officer&#146;s
short-term incentive award for fiscal 2008, salary for 2009 and long-term incentive award in the
form of stock options. With the exception of in camera sessions of the Compensation Committee and
Board of Directors to review, recommend and approve the Chief Executive Officer&#146;s own compensation,
the Chief Executive Officer was present at all deliberations of the Compensation Committee and the
Board of Directors related to executive compensation.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In the first quarter of 2009, the Chief Executive Officer recommended to the Compensation Committee
the adoption of a short-term incentive awards program to formalize and systematize our short-term
incentive awards policies, which had previously been set forth in individual employment agreements
and otherwise established by corporate practice. In March&nbsp;2009, the Compensation Committee
recommended to the Board of Directors, and the Board of Directors adopted, the short-term incentive
awards program. The Chief Executive Officer was present at the relevant meetings of the
Compensation Committee and Board of Directors. For more information on our short-term incentive
awards program, see the section below entitled &#147;Short-Term Incentive Awards.&#148;
</DIV>
<DIV align="left">
<A name="130"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Benchmarking of Executive Compensation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As part of its evaluation, the Compensation Committee utilized compensation information from the
2008 Radford Global Life Sciences Survey (the &#147;Radford Survey&#148;) for companies under 50 employees,
except in circumstances where survey information for a particular position was not available in the
companies under 50 employee section of the survey, in which case the broader Global Life Sciences
Survey was used. The Radford Survey represents a nationally-based assessment of compensation,
widely used within the pharmaceutical and biotechnology industry sectors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Compensation Committee believes that focusing on a range around the 50th percentile of the
Radford Survey for base salaries and incentive compensation provides the tools to allow a company
of our size to competitively attract and retain talented officers by reflecting consideration of
our stockholders&#146; interest in paying what is necessary, but not significantly more than necessary,
to achieve Company goals, while conserving cash and equity as much as possible. The Compensation
Committee realizes that using a benchmark at this point in our development is an essential tool but
not the only means for gathering and validating market data. In instances where an executive
officer is uniquely key to our success, the Compensation Committee may provide compensation in
excess of the benchmark. Variations may also occur as a result of the experience level of the
individual and market factors. The Compensation Committee believes that, given the competitive
industry in which we operate and the company culture that we have created, our base compensation
and equity programs are flexible and generally sufficient to retain our existing executive officers
and to hire new executive officers when needed and required. The main objective of our compensation
program is to align the strategic interests of our executive officers and stockholders. To achieve
this objective, we understand that we must attract and retain individuals with the appropriate
expertise and leadership ability. Once we have recruited a talented executive, we must motivate and
reward him or her to build long-term stockholder value. Our competition for talent is significant
and we recruit from a limited pool of experienced and successful resources. Our unique talent base
includes executive officers who are nationally and internationally recognized for their expertise
and leadership. Accordingly, our compensation program must be competitive in a challenging and
dynamic labor market.
</DIV>
<DIV align="left">
<A name="131"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Elements of Executive Compensation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We have designed and implemented compensation policies that have allowed us to recruit within and
from outside the Seattle, WA and Vancouver, BC areas while balancing fixed and variable pay costs
for a long-term, sustainable approach to talent acquisition and retention. Our executive
compensation consists of the following elements: base salary, cash incentives and stock option
grants, each of which is discussed in detail below.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Base Salary</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We provide an annual salary based on comparable market data for level of responsibility, expertise,
skills, knowledge, experience, our unique organizational requirements and desire to maintain
internal equity. Although the program generally is designed to deliver executive base salaries
within a range of 10% around the 50th percentile of salaries for executives with the requisite
skills in similar positions with similar responsibilities at comparable companies, executives with
more experience, critical skills and/or considered key performers may be compensated above the
range as part of the Company&#146;s strategy for attracting, motivating and retaining highly experienced
and high performing employees. The Compensation Committee reviews base salaries in the fourth
quarter of each year and may make adjustments from time to time to realign salaries with market
levels after taking into account individual responsibilities, performance and experience. The
primary factors in the Compensation Committee&#146;s consideration of 2009 salary included additional
public company responsibilities as a result of the Arrangement, anticipated increases in the labor
market, and the executive&#146;s overall contribution and value to the organization. 2008 salaries for
our current Chief Executive Officer, Chief Financial Officer and Chief Medical Officer were
established by OncoGenex Technologies prior to the Arrangement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Cash Incentives</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The executive officers&#146; annual target cash incentive compensation is determined as a percent of
annual salary. This is a variable, at-risk part of annual compensation that the Board of Directors
or the Compensation Committee may or may not award and may modify based on Company and, in most
cases, individual performance. Each year the Board of Directors or the Compensation Committee
establish a target annual incentive compensation pool based on a percentage of each executive&#146;s
base salary and the achievement of corporate goals and linked objectives. The targets generally
have ranged from 25% to 40% of an executive&#146;s salary. The Board of Directors and the Compensation
Committee have the sole authority to award annual incentive compensation to our executive officers.
The Compensation Committee recommends to the full Board of Directors annually, based on the
assessment of goal achievement, the
level of cash incentive to be paid either above, below or at target and the timing of the payout.
We utilize annual incentive compensation to compensate officers for achieving strategic and
operational goals. These goals relate generally to strategic factors such as establishment and
maintenance of key strategic relationships, and development of our product candidates and to
financial factors such as raising capital, improving our results of operations and increasing the
price per share of our common stock.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Stock Option Grants</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We provide long-term incentives in the form of stock options. This incentive is another form of
at-risk compensation. The number of options granted is discretionary and the value earned on any
grant varies with the stock price over the option term. In large part due to the length of product
development cycles, it is critical for our business to align the interests of executive officers
and stockholders, and to retain executive officers by means of what we hope will be long-term
wealth creation in the value of their stock options, which have vesting provisions that encourage
continued employment while achieving interim product development milestones. We have historically
elected to use stock options as the primary long-term equity incentive vehicle. Stock option grants
are made at the commencement of employment, may be made annually based on performance and,
occasionally, following a significant change in job responsibilities or, to meet other special
objectives, including strategic goals and retention. The Compensation Committee recommends to the
Board of Directors for approval stock option awards for executive officers based on a review of
competitive compensation data, its assessment of individual performance, a review of each
executive&#146;s existing long-term incentives and retention considerations. In determining the number
of stock options to be granted to executives, the Compensation Committee and the Board of Directors
also take into account the individual&#146;s position, scope of responsibility, ability to affect
strategic business operations and stockholder value and the value of stock options in relation to
other elements of the individual executive&#146;s total compensation. We expect to continue to use stock
options as a long-term incentive vehicle because:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Stock options align the interests of executives with those of the stockholders, support
a pay-for-performance culture, foster employee stock ownership and focus the management
team on increasing value for the stockholders;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Stock options help to provide a balance to the overall executive compensation program as
base salary and our cash incentive compensation program focus on short-term compensation,
while the vesting of stock options increases stockholder value over the longer term; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The vesting period of stock options encourages executive retention as long as the
options remain in the money.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Radford Survey benchmarking assessment validated the overall management and use of stock
options, as the equity vehicle was well within industry norms and competitive with the surveyed
companies.
</DIV>
<DIV align="left">
<A name="132"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Stock Ownership Guidelines</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Although stock option awards encourage equity ownership, we currently do not require our directors
or executive officers to own a particular amount of our common stock. The Compensation Committee
believes that stock and option holdings among our directors and executive officers are sufficient
at this time to provide motivation and to align this group&#146;s interests with those of our
stockholders.
</DIV>
<DIV align="left">
<A name="133"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Perquisites</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our executive officers participate in the same group insurance and employee benefit plans as our
other salaried employees. At this time we do not provide special benefits or other perquisites to
our executive officers.
</DIV>
<DIV align="left">
<A name="134"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>2008 Named Executive Officer Compensation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Salary</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As a consequence of the Arrangement, an entirely new management team was established. Each of the
Company&#146;s current Named Executive Officers was previously an employee of OncoGenex Technologies,
and, accordingly, his or her base salary for 2008 had been established by OncoGenex Technologies at
a time when it was a private Canadian life science company. Following the Arrangement, special
consideration was required in evaluating each such Named Executive Officer&#146;s base salary and
appropriate adjustments for 2009 because the compensation practices of private Canadian life
sciences companies differ materially from compensation packages for public U.S. life sciences
companies. In the fourth quarter of 2008, the Compensation Committee and the Board of Directors
evaluated the base salaries of our Named Executive Officers and approved the adjustments set forth
below for 2009.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Scott Cormack has driven the Company&#146;s performance, leading it from the early start-up phase
through development to proof of scientific concept in humans, and completing the Arrangement
resulting in a public entity. In an executive session, the Compensation Committee assessed
Mr.&nbsp;Cormack&#146;s performance. The Compensation Committee considered OncoGenex&#146; and Mr.&nbsp;Cormack&#146;s
accomplishment of core Company objectives including clinical development and the completion of a
financing or merger, as well as his instrumental role in partnering and strategic discussions.
Based on these factors and a review of chief executive officer salaries reported in the Radford
Survey, the Compensation Committee recommended, and the Board of Directors set, Mr.&nbsp;Cormack&#146;s
salary at the level that is reflected in the Summary Compensation Table below. Mr.&nbsp;Cormack&#146;s base
salary for 2009 equals approximately 97% of the 50th percentile of the Radford Survey.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Steve Anderson is the Company&#146;s Chief Financial Officer. In establishing Mr Anderson&#146;s base salary,
the Compensation Committee considered, among other things, Mr.&nbsp;Anderson&#146;s current responsibilities
in comparison to other U.S. public biotechnology company chief financial officers. Based on this
factor and a review of chief financial officer salaries reported in the Radford Survey, the
Compensation Committee recommended, and the Board of Directors set, Mr.&nbsp;Anderson&#146;s salary at the
level reflected in the Summary Compensation Table. Mr.&nbsp;Anderson&#146;s base salary for 2009 equals
approximately 83% of the 50th percentile of the Radford Survey.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dr.&nbsp;Cindy Jacob is the Company&#146; Executive Vice President and Chief Medical Officer. The
Compensation Committee in determining 2009 salary considered Dr.&nbsp;Jacob&#146;s important role in
furthering the development of clinical assets, extensive experience in obtaining FDA approval for
product candidates, as well as her instrumental role in partnering and strategic discussions. Based
on these factors and a review of the salaries of executives reported in the Radford Survey, the
Compensation Committee set Dr.&nbsp;Jacob&#146;s salary at the level reflected in the Summary Compensation
Table. Dr.&nbsp;Jacob&#146;s base salary for 2009 equals approximately 116% of the 50th percentile of the
Radford Survey.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Cash Incentives</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">During 2008, the short-term incentive awards available to our current Named Executive Officers were
based on a pre-determined percentage of the executive&#146;s base salary, dependent upon the achievement
during the fiscal year of certain corporate goals established by OncoGenex Technologies prior to
the Arrangement. Prior to year end, the Compensation Committee assessed the performance of the
corporate goals as set by OncoGenex Technologies prior to the Arrangement, specifically:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Clinical Development: We successfully completed the analysis of the clinical benefit of
OGX-011 in combination with first-line chemotherapy in patients with castrate resistant
prostate cancer, in combination with second-line chemotherapy in patients with castrate
resistant prostate cancer and in combination with first-line chemotherapy in patients with
non-small cell lung cancer. We also successfully completed enrolment of our phase 1 dose
escalation clinical trials with each of OGX-427 as a monotherapy and with SN2310 in
patients with solid tumors.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Operations: We successfully completed the Arrangement, making greater financial
resources available to OncoGenex Technologies and resulting in a combined company with a
deeper product candidate pipeline.</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Regulatory Development: We reached an agreement with the FDA via the special protocol
assessment process for our phase 3 clinical trial with OGX-011 in combination with
second-line chemotherapy in patients with castrate resistant prostate cancer featuring
survival as the primary endpoint. We also successfully achieved Fast Track designation with
the FDA for OGX-011 in advanced metastatic prostate cancer.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">After discussion and assessment of the objectives established, the Compensation Committee
determined that they had been satisfied. Accordingly, the current Named Executive Officers were
awarded their maximum potential short-term incentive awards. The maximum potential short-term
incentive award for each of our executive officers was as follows:
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Maximum Potential Short-term</B></TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Executive Officer</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Incentive Award</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD align="center" valign="top">Chief Executive Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">40% of salary</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">Chief Financial Officer
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">25% of salary</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD align="center" valign="top">Chief Medical Officer/EVP
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">30% of salary</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In March&nbsp;2009, the Board of Directors approved a written short-term incentive awards program
(&#147;STIP&#148;), which is intended to supersede in their entirety the prior practices of Sonus and
OncoGenex Technologies with respect to short-term incentive awards, and to set forth in a single
location the Company&#146;s policy on short-term incentive awards. As it applies to our Named Executive
Officers, the STIP provides an annual opportunity for them to receive a discretionary cash bonus
based on the attainment of corporate objectives, which the Company believes correlate with the
growth of long-term shareholder value. Under the STIP, the Compensation Committee determines the
corporate objectives that will apply for each respective year. The Company does not publicly
disclose the specific corporate objectives set for the current short-term incentive awards because
disclosure of such information, which reflects our confidential business plans, could result in
competitive harm, and such information may therefore be omitted pursuant to Instruction 4
to Item 402(b) of Regulation&nbsp;S-K and in accordance with Securities Act Rule&nbsp;406 and Exchange Act
Rule&nbsp;24b-2. Our corporate objectives are designed to be stretch objectives in order to drive
sustainable growth and performance on an individual basis, and there is a risk that payments will
not be made at all or will be made at less than 100% of the target amount. The targets are set such
that they are attainable only with significant effort while at the same time still making them
achievable.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Long-Term Incentive Awards</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Awards of stock options are an important component of our Named Executive Officer long-term
incentive pay and are granted as part of the annual performance cycle. Each of our executive
officers receives stock option grants under the Company&#146;s stock option plans. All of our full-time
employees are eligible for stock option grants designed to reward persistent and committed
performance over time. We believe that broad-based participation in our option program supports the
alignment of employee and stockholder interests. Stock options granted to each executive officer
are made on a discretionary basis by the Compensation Committee, taking into consideration Company
and individual objectives, as well as retentive factors for key contributors.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The precise amount of equity granted to each Named Executive Officer for the 2008 fiscal year was
determined based on the Radford Survey data, the experience of the executive, the breadth of his or
her knowledge and skill set, internal considerations and individual performance during the fiscal
year. In addition, the Compensation Committee considered the amount of the executives&#146;
then-existing holdings of the Company, as well as the limited amount of equity available for grant
under the Company&#146;s various equity compensation plans. The number of stock options granted was
calculated using the Black-Scholes option pricing model to attain the targeted economic value as
determined based on the Radford Survey data and other criteria described above. The stock option
awards for our Named Executive Officers were granted effective on December&nbsp;31, 2008 with a seven
year term, vesting over four years with 25% vesting on each of the first four anniversaries of the
grant date, and an exercise price equal to the closing price of the common stock on the Nasdaq
Capital Market on the date of grant. Although no objective formula was utilized when determining
the relative proportion of equity awards to total compensation, the Compensation Committee
considered the Radford Survey to inform its decision process.
</DIV>
<DIV align="left">
<A name="135"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Other Policies and Considerations</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Internal Pay Equity</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Compensation Committee reviewed the Radford Survey and concluded that total compensation for a
company&#146;s chief executive officer is generally higher than the total compensation of either its
chief financial officer or the chief medical officer and the total compensation of the chief
medical officer is generally higher than the total compensation of the chief financial officer.
However, Scott Cormack has historically elected to have less salary compensation in favour of
greater equity compensation, whereas Cindy Jacobs has historically elected to have greater salary
compensation in favour of less equity compensation. The preferences of these executives results in
a difference in the proportion of salary and equity for these executives and has resulted in Cindy
Jacobs having a higher salary than Scott Cormack.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Employment Agreements and Termination Benefits</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Company has employment agreements with each of its Named Executive Officers. Such employment
agreements were adopted by OncoGenex Technologies prior to the Arrangement and contain provisions
related to termination and, in the case of our Chief Executive Officer and Chief Financial Officer,
change of control. For 2008, the Compensation Committee considered the accumulated wealth of the
executive officers and whether the executive officers need the termination and change of control
protection provided by the employment agreements. Since the exercise price of the executive&#146;s stock
options are approximately equal to the current stock price of the Company, it was determined that
the executives have not accumulated material wealth from the Company. Further, in the event of
termination, and in consideration of the time required for an executive to find similar employment,
the termination provisions were considered appropriate. The specific terms of these arrangements,
as well as an estimate of the compensation that would have been payable had they been triggered as
of fiscal year-end, are described in detail in the section below entitled &#147;Potential Payments Upon
Termination&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">During 2009, the Company intends to amend and restate each of the employment agreements currently
in place with our Named Executive Officers.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Savings Plan</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Company maintains a 401(k) plan pursuant to which it may provide employer matching
contributions, in a specified percentage, to eligible employees who elect to make elective deferral
contributions. Previously, certain employer matching contributions were invested in employer
securities. However, following the Arrangement, the Board of Directors of OncoGenex amended and
restated the 401(k) plan whereby securities of the Company are no longer offered as an investment
option. Thus, no employer matching contributions subsequent to the restatement of the 401(k) plan
have been, or are permitted to be, invested in OncoGenex shares. Furthermore, any contributions invested in OncoGenex shares prior to such restatement have since
been invested in securities other than those of OncoGenex or rolled over into individual retirement
accounts. Because no shares of the Company were contributed to the 401(k) plan subsequent to such
restatement, no related expense has been incurred since such time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Employee Stock Purchase Plan</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">During 2008, the Company maintained an employee stock purchase plan (&#147;ESPP&#148;) that was intended to
qualify as an &#147;employee stock purchase plan&#148; under Section&nbsp;423 of the Internal Revenue Code of
1986, as amended. The ESPP allowed all employees, including our Named Executive Officers, to
purchase shares of the Company&#146;s common stock through payroll deductions of up to 10% of their
respective annual eligible compensation, subject to a maximum of $25,000 per year. The price of the
common stock purchased pursuant to the ESPP was equal to 85% of the lower of the fair market value
of the common stock on the commencement date of each twelve-month offering period or the specified
purchase date. Subsequent to December&nbsp;31, 2008, the Company terminated the ESPP.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Tax and Accounting Implications</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Beginning on January&nbsp;1, 2006, the Company began accounting for stock based payments, including its
stock option grants, in accordance with the requirements of FASB Statement 123(R).
</DIV>
<DIV align="left">
<A name="136"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Compensation Committee Interlocks and Insider Participation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">No member of the Compensation Committee during fiscal year 2008 served as an officer, former
officer or employee of the Company. During fiscal year 2008, no executive officer of the Company
served as a member of the Compensation Committee of any other entity, one of whose executive
officers served as a member of the Company&#146;s Board of Directors or Compensation Committee, and no
executive officer of the Company served as a member of the Board of Directors of any other entity,
one of whose executive officers served as a member of the Company&#146;s Compensation Committee.
</DIV>
<DIV align="left">
<A name="137"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Report of the Compensation Committee on Executive Compensation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Compensation Committee of the Board of Directors has reviewed and discussed the Compensation
Discussion and Analysis required by Item 402(b) of Regulation&nbsp;S-K with management and, based on
such review and discussions, the Compensation Committee recommended to the Board of Directors that
the Compensation Discussion and Analysis be included in the Company&#146;s 2008 Annual Report on
Form 10-K and this proxy statement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Compensation Committee:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dwight Winstead, Chairman<BR>
Michelle Burris<BR>
Neil Clendeninn

</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left">
<A name="138"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>EXECUTIVE COMPENSATION</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In connection with the Arrangement, our previous President and Chief Executive Officer, Michael
Martino, and our previous Chief Financial Officer, Alan Fuhrman, resigned their respective
positions, and the Company appointed the following persons to serve as the officers of the Company:
Scott Cormack as the Company&#146;s Chief Executive Officer and President, Stephen Anderson as the
Company&#146;s Chief Financial Officer and Secretary and Cindy Jacobs, Ph.D., M.D., as the Company&#146;s
Executive Vice President and Chief Medical Officer. Collectively, Scott Cormack, Stephen Anderson,
Cindy Jacobs, Michael Martino and Alan Fuhrman are our &#147;Named Executive Officers&#148;.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following table provides information regarding our current executive officers and certain key
persons.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="28%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="39%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Name and Municipality of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Director</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Residence</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Age</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Position with the Company</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Since</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><I>Executive Officers</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>

<TR valign="top" style="padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Scott Cormack, <BR>
Richmond, Canada </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">44</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left">President, Chief Executive Officer and Director</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">2008</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Stephen Anderson,
<BR>
West Vancouver, <BR>
Canada</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">46</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left">Chief Financial Officer and Secretary</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">n/a</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Cindy Jacobs,
<BR>
Fall City,<br> Washington </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">51</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left">Executive Vice President and Chief Medical Officer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">n/a</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px"><I>Key Persons</I></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Martin Gleave, <BR>
Vancouver, Canada</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">50</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left">Chief Scientific Officer</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">n/a</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="top" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:0px; text-indent:-0px">Monica Krieger,
Seattle Washington</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">60</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="3" align="left">Vice President of Regulatory Affairs</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center">n/a</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Following are the biographies of our current Named Executive Officers and certain key employees,
except that the biography of Scott Cormack is located above under the heading &#147;Board of Directors &#151;
General&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Stephen Anderson</I>, 46, has served as the Company&#146;s Chief Financial Officer and Secretary since
August&nbsp;21, 2008, and had been OncoGenex Technologies&#146; Chief Financial Officer since January&nbsp;2006
and its Secretary since August&nbsp;2006. From 2005 to 2006, Mr.&nbsp;Anderson served as Chief Financial
Officer at Perceptronix Medical Inc., a medical diagnostic company. From 2003 to 2005, he served as
President of his consulting company, SLA Enterprises Ltd. From 1998 to 2003, he served in various
positions at Westport Innovations Inc., an alternative energy company, including Secretary,
Controller, Vice President, Finance and Chief Financial Officer. Mr.&nbsp;Anderson holds Bachelor of
Arts and Master of Business Administration degrees from the University of British Columbia. He is a
Chartered Accountant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Cindy Jacobs</I>, Ph.D., M.D., 51, has served as the Company&#146;s Executive Vice President and Chief
Medical Officer since August&nbsp;21, 2008, and had been OncoGenex Technologies&#146; Executive Vice
President and Chief Medical Officer since September&nbsp;2005. From 1999 to 2005, Dr.&nbsp;Jacobs served as
Chief Medical Officer and Senior Vice President, Clinical Development of Corixa Corporation, a
biopharmaceutical company (now a subsidiary of Glaxo-Smith-Kline). Prior to 1998, Dr.&nbsp;Jacobs held
Vice President, Clinical Research positions at two other biopharmaceutical companies. Dr.&nbsp;Jacobs
received her Ph.D. in Veterinary Pathology/Microbiology from Washington State University and M.D.
from the University of Washington Medical School.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Martin Gleave</I>, M.D., 50, a key person of the Company, has been the Company&#146;s Chief Scientific
Officer since August&nbsp;21, 2008. He was a co-founder of OncoGenex Technologies, the principal
inventor of its product candidates, and had been its Chief Science Officer since May&nbsp;2000. In
addition to his part-time duties at the Company, Dr.&nbsp;Gleave is a Distinguished Professor and
Research Director in the Department of Urologic Sciences at the University of British Columbia
since 2000, and Director of the Prostate Centre since 1993. He has also been a Senior Research
Scientist at the Prostate Research Lab at Vancouver General Hospital and the Department of Cancer
Endocrinology at BC Cancer Agency since 1992. Dr.&nbsp;Gleave has been a consultant Urologist for the
Department of Urology at the University of Washington since 1997. Dr.&nbsp;Gleave received his M.D. from
the University of British Columbia in 1984, his Fellow at the Royal College of Surgeons of Canada
(FRCSC)&nbsp;in 1989, his Urologic Oncology Fellowship, University of Texas MD Anderson Cancer Center in
1992 and Fellow of the American College of Surgeons (FACS)&nbsp;in 1998.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Monica Krieger</I>, Ph.D., M.D., 60, a key person of the Company, has served as Vice President,
Regulatory Affairs at the Company since August&nbsp;21, 2008, and, prior to such time, had been
OncoGenex Technologies&#146; Vice President, Regulatory Affairs, since September&nbsp;2005. From 1999 to
2005, Dr.&nbsp;Krieger served as Vice President, Regulatory Affairs of Corixa Corporation, a
biopharmaceutical company (now a subsidiary of Glaxo-Smith-Kline). Prior to 1999, Dr.&nbsp;Krieger
headed the Regulatory Affairs department at three other biopharmaceutical companies. She received a
Ph.D. from Rutgers University and an MBA from the Darden School at the University of Virginia.
</DIV>
<DIV align="left">
<A name="139"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Summary Compensation Table</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following table sets forth information regarding the compensation of our Named Executive
Officers for each of the fiscal years ended December&nbsp;31, 2008, 2007 and 2006. The components of the
compensation reported in the Summary Compensation Table are described below. Additional information
on the components of the total compensation package, including a discussion of the proportion of
each element to total compensation, is discussed in the Compensation Discussion and Analysis.
</DIV>
<DIV align="center">
<TABLE style="font-size: 9pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="23%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Non-Equity</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Incentive</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>All</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Plan</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Other</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left"><B>Name and</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Salary</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Bonus</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Option Awards</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Compensation</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Compensation</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Total</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Principal Position</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Year</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)(1)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)(2)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<TR>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Scott Cormack,</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">97,874</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">183,875</TD>
    <TD nowrap>(5)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">281,749</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">President, Chief
Executive Officer
and <font style="white-space: nowrap">Director (3)
(4)</font></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stephen Anderson,</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">60,612</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,185</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">70,169</TD>
    <TD nowrap>(6)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">136,966</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Chief Financial
<font style="white-space: nowrap">Officer (3) (4)</font></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cindy Jacobs,</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">127,605</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,403</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">181,988</TD>
    <TD nowrap>(7)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">311,996</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Executive Vice
President and Chief
Medical Officer (4)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Michael A. Martino,
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">251,356</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">240,206</TD>
    <TD nowrap>(9)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1,138,340</TD>
    <TD nowrap>(10)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,629,902</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Former President and</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">376,380</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">338,120</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">12,304</TD>
    <TD nowrap>(11)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">726,804</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-0px">Chief Executive
Officer; Director
(8)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">374,040</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">222,245</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">175,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">15,513</TD>
    <TD nowrap>(12)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">786,798</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alan Fuhrman,</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">170,901</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">133,305</TD>
    <TD nowrap>(13)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">262,049</TD>
    <TD nowrap>(14)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">566,255</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Former Senior Vice</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2007</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">255,900</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">184,130</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">7,486</TD>
    <TD nowrap>(15)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">447,516</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-0px">President and Chief</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2006</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">245,699</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">137,780</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">94,900</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">8,439</TD>
    <TD nowrap>(16)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">486,818</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-0px">Financial Officer
(8)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>





<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes amounts earned but deferred at the election of our Named Executive Officer, such as
salary deferrals under the Company&#146;s 401(k) Plan established under Section 401(k) of the
Internal Revenue Code.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>This column reflects the dollar amount recognized for financial statement reporting purposes
for each fiscal year in accordance with FAS 123(R) and thus includes amounts from awards
granted prior to each respective fiscal year-end. Assumptions used in the calculation of the
amounts in this column are included in footnote 12 to the Company&#146;s audited financial
statements included in our Annual Report on Form 10-K. The following Named Executive Officers
forfeited option awards during 2008:</TD>
</TR>

</TABLE>


<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Michael A. Martino: 64,507 options expired with a weighted average exercise price
of $96.48</TD>
</TR>

<TR style="font-size: 8pt">
    <TD>&nbsp;</TD>
</TR> <TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="8%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Alan Fuhrman: 29,055 options expired with a weighted average exercise price of
$42.04</TD>
</TR>

</TABLE>
</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>Mr.&nbsp;Cormack and Mr.&nbsp;Anderson are paid in Canadian dollars, and thus, the amounts shown in the
columns for salary and bonus have been translated into U.S. dollars based on average foreign
exchange rates.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(4)</TD>
    <TD>&nbsp;</TD>
    <TD>Became Named Executive Officers of the Company on August&nbsp;21, 2008 following the Arrangement.
Compensation reported herein therefore includes the period of August&nbsp;21, 2008 to December&nbsp;31,
2008.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(5)</TD>
    <TD>&nbsp;</TD>
    <TD>Of the $183,875 in Non-Equity Incentive Plan Compensation paid to Mr.&nbsp;Cormack during 2008,
$106,400 was paid out based on 40% of his 2008 annualized salary of $265,999 and $77,475 was
paid in relation to the completion of the arrangement.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(6)</TD>
    <TD>&nbsp;</TD>
    <TD>Of the $70,169 in Non-Equity Incentive Plan Compensation paid to Mr.&nbsp;Anderson during 2008,
$41,182 was paid out based on 25% of his 2008 annualized salary of $164,730 and $28,986 was
paid in relation to the completion of the arrangement.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(7)</TD>
    <TD>&nbsp;</TD>
    <TD>Of the $181,988 in Non-Equity Incentive Plan Compensation paid to Ms.&nbsp;Jacobs during 2008,
$104,040 was paid out based on 30% of her 2008 annualized salary of $346,800 and $77,948 was
paid in relation to the completion of the arrangement.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(8)</TD>
    <TD>&nbsp;</TD>
    <TD>All compensation (except severance) set forth herein for Mr.&nbsp;Martino and Mr.&nbsp;Fuhrman was
earned by such persons prior to the Arrangement. Because the Arrangement was accounted for as
a reverse takeover whereby the historical results of Sonus are excluded from the financial
statements, such compensation (except severance) of Mr.&nbsp;Martino and Mr.&nbsp;Fuhrman is not
reflected in our consolidated financial statements. Mr.&nbsp;Martino&#146;s compensation for service as
a non-employee director for the time period subsequent to the Arrangement is excluded from
this table and is instead included in the table under the heading &#147;Director Compensation Paid
for 2008&#148;. Mr.&nbsp;Martino did not receive any compensation for his services as a director prior
to the Arrangement, as the Company does not provide director compensation to directors who are
also employees of the Company.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(9)</TD>
    <TD>&nbsp;</TD>
    <TD>64,507 options expired during 2008 with a weighted average exercise price of $96.48.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(10)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes $1,129,946 in termination benefits paid in connection with the Arrangement pursuant
to Mr.&nbsp;Martino&#146;s change of control arrangement, $550 in matching 401(k) contributions, $1,869
in executive life insurance premium payments and $5,975 in executive disability premium
payments.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(11)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes $4,200 in matching 401(k) contributions, $1,869 in executive life insurance premium
payments and $6,235 in executive disability premium payments.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(12)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes $7,292 in matching 401(k) contributions, $2,294 in executive life insurance premium
payments and $5,927 in executive disability premium payments.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(13)</TD>
    <TD>&nbsp;</TD>
    <TD>29,055 options expired during 2008 with a weighted average exercise price of $42.04.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(14)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes $258,389 in termination benefits paid in connection with the Arrangement pursuant to
Mr.&nbsp;Fuhrman&#146;s change of control arrangement, $374 in matching 401(k) contributions, $952 in
executive life insurance premium payments and $2,334 in executive disability premium payments.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(15)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes $4,200 in matching 401(k) contributions, $952 in executive life insurance premium
payments and $2,334 in executive disability premium payments.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(16)</TD>
    <TD>&nbsp;</TD>
    <TD>Includes $4,937 in matching 401(k) contributions, $1,168 in executive life insurance premium
payments and $2,334 in executive disability premium payments.</TD>
</TR>

</TABLE>

<DIV align="left">
<A name="140"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Fiscal 2008 Grants of Plan-Based Awards</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following table provides information related to grants of plan-based awards to our Named
Executive Officers during the 2008 fiscal year.
</DIV>
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="10"><B>Estimated Future</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Grant Date</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="10"><B>Payouts Under</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>All Other</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>All Other</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Fair Value of</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="10"><B>Non-Equity</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Option Awards:</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Stock</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="10" style="border-bottom: 1px solid #000000"><B>Incentive Plan Awards (1)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Awards: #</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B># of Securities</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise or Base</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Award and Option</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Grant</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Threshold</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Target</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Maximum</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>of Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Underlying</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Price of Option</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Awards</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Date</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>of Stock</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Options (2)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Awards ($/Sh)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(5)($)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="top" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Scott Cormack</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">December 31, 2008</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&#151;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">183,875</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">183,875</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&#151;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">100,000</TD>
    <TD nowrap valign="top">(3)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.00</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">194,674</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="top" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stephen Anderson</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">December 31, 2008</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&#151;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">70,169</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">70,169</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&#151;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">40,000</TD>
    <TD nowrap valign="top">(4)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.00</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">77,870</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<TR valign="top" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cindy Jacobs</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">December 31, 2008</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&#151;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">181,988</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">181,988</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">&#151;</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">70,000 </TD>
    <TD nowrap valign="top">(3)</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">3.00</TD>
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">136,269</TD>
    <TD valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>This column represents the non-equity incentive plan awards granted to our Named Executive
Officers during the 2008 fiscal year, which were earned based on Company performance during
the year. As a result, this table shows the awards that were possible at the threshold, target
and maximum levels of performance. The Summary Compensation Table shows the actual non-equity
incentive awards earned by our Named Executive Officers. The Company does not publicly
disclose the specific corporate objectives set for the short-term incentive awards because
disclosure of such information could result in competitive harm.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>The stock options vest at a rate of 25% of the underlying shares on each of the first four anniversaries of December&nbsp;31, 2008.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>Stock options were granted under the 2000 Stock Incentive Plan.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(4)</TD>
    <TD>&nbsp;</TD>
    <TD>Stock options were granted under the OncoGenex Technologies Inc. Amended and Restated Stock Option Plan.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(5)</TD>
    <TD>&nbsp;</TD>
    <TD>The amounts reported in this column reflect the fair value of these awards on the grant date
as determined under the principles used to calculate the value of equity awards for purposes
of the Company&#146;s financial statements and may or may not be representative of the value
eventually realizable by the executive. For a discussion of the assumptions and methodologies
used to value the awards reported in this column, please see footnote 12 to our audited
consolidated financial statements, which are included in our 2008 Annual Report on Form 10-K.</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left">
<A name="141"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Outstanding Equity Awards at Fiscal Year-End</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following table provides information regarding the outstanding equity awards held by our Named
Executive Officers as of December&nbsp;31, 2008.
</DIV>

<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="18" style="border-bottom: 1px solid #000000"><B>Option Awards</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Equity Incentive Plan</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Number of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Awards: Number of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Securities</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Number of</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Securities Underlying</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Option</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Underlying</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Securities Underlying</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Unexercised Unearned</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Option</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Unexercised Options</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Unexercised Options</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Options</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Price</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Expiration</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(#) Exercisable</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(#) Unexercisable</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(#)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Date</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Scott Cormack,</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20,470</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.89</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">12/16/10</TD>
    <TD nowrap>(1)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">President, Chief</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21,559</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.89</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">1/14/11</TD>
    <TD nowrap>(1)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Executive Officer and Director</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46,167</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4.11</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">8/8/12</TD>
    <TD nowrap>(1)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">12/31/15</TD>
    <TD nowrap>(2)(3)</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stephen Anderson,</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">16,332</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">5,444</TD>
    <TD nowrap>(4)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4.11</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3/23/13</TD>
    <TD nowrap>(1)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Chief Financial Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">12/31/15</TD>
    <TD nowrap>(2)(5)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em; background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cindy Jacobs,</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,203</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4.11</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">9/12/12</TD>
    <TD nowrap>(1)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Executive Vice</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">70,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">12/31/15</TD>
    <TD nowrap>(2)(3)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">President and Chief
Medical Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 0em"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Michael A. Martino,</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">7,094</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">108.00</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">2/9/10</TD>
    <TD nowrap>(6)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Former President</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23,611</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6.66</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">3/18/18</TD>
    <TD nowrap>(7)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">and Chief Executive
Officer; <font style="white-space: nowrap">Director
(8)</font></DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>These stock options were granted prior to the Arrangement pursuant to the OncoGenex
Technologies Inc. Amended and Restated Stock Option Plan and were assumed by the Company in
connection with the Arrangement.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>These stock options vest at a rate of 25% of the underlying shares on each of the first four
anniversaries of December&nbsp;31, 2008.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>These stock options were granted under the 2000 Stock Incentive Plan.
</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(4)</TD>
    <TD>&nbsp;</TD>
    <TD>These stock options vested on January&nbsp;9, 2009.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(5)</TD>
    <TD>&nbsp;</TD>
    <TD>These stock options were granted under the OncoGenex Technologies Inc. Amended and Restated
Stock Option Plan.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(6)</TD>
    <TD>&nbsp;</TD>
    <TD>These stock options were granted under the Incentive Stock Option, Nonqualified Stock Option
and Restricted Stock Purchase Plan &#151; 1991.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(7)</TD>
    <TD>&nbsp;</TD>
    <TD>These stock options were granted under the 2007 Performance Incentive Plan.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(8)</TD>
    <TD>&nbsp;</TD>
    <TD>This table excludes the 17,000 stock options granted to Mr.&nbsp;Martino in 2008 for his service
as a non-employee director of the Company subsequent to the Arrangement. Such stock options
are instead reflected in the table under the heading &#147;Director Compensation Paid for 2008.&#148;
Mr.&nbsp;Martino did not receive a grant of stock options in connection with his services as a
director prior to the Arrangement, as the Company does not provide director compensation to
directors who are also employees of the Company.</TD>
</TR>

</TABLE>

<DIV align="left">
<A name="142"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Option Exercises and Stock Vested</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following table provides information related to options exercised by our Named Executive
Officers during the 2008 fiscal year.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="66%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 1px solid #000000"><B>Option Awards</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Number of Shares</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Acquired on</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Value Realized on</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Exercise</B></TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>(#)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>($)</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Scott Cormack,</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">24,809</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">14,407</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">
President, Chief
Executive Officer and Director</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Body --></TABLE>
</DIV>

<DIV align="left">
<A name="143"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Pension Benefits/Nonqualified Deferred Compensation</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Company does not have any plan that provides for payments or other benefits at, following, or
in connection with retirement. The Company also does not have a plan that provides for the deferral
of compensation for any employee.
</DIV>
<DIV align="left">
<A name="144"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Potential Payments Upon Termination/Change of Control</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Change of Control Under Our Equity Compensation Plans</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The following discussion sets forth the change of control provisions provided for in our various
equity compensation plans.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U>1999 Nonqualified Stock Incentive Plan and 2000 Stock Incentive Plan</U>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Under our 1999 Nonqualified Stock Incentive Plan (the &#147;1999 Plan&#148;) and our 2000 Stock Incentive
Plan (the &#147;2000 Plan&#148;), the administrator of such plans may take one of the following actions in
connection with a change of control, as applicable:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>provide for the purchase of each outstanding award, or, in the case of the 1999 Plan
only, the exchange of each such award; or</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>adjust the terms of such awards (1)&nbsp;in a manner to cause them to be assumed, or new
rights substituted therefor by another entity, (2)&nbsp;in a manner to be determined by the
administrator to reflect the change of control or (3)&nbsp;in such other manner as the
administrator considers equitable.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If the administrator does not take any of the forgoing actions, all awards shall terminate upon the
consummation of the change of control.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As used in the 1999 Plan and the 2000 Plan, the term &#147;change of control&#148; means the occurrence of
any of the following events, as applicable:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>acquisitions of securities of the Company representing 50% or more of certain
outstanding securities of the Company;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a merger or consolidation in which the Company is not the surviving entity, except for a
transaction, the principal purpose of which is to change the state in which the Company is
incorporated;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>certain significant sales, transfers or other dispositions of assets of the Company;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>any reverse merger in which the Company is a surviving entity but in which securities
possessing more than 50% of the total combined voting power of the Company&#146;s outstanding
securities are transferred to a person or persons different from the persons holding those
securities immediately prior to such reverse merger;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>dissolution of the Company;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>under the 1999 Plan, a liquidation of more than 50% in value of the Company, or, under
of the 2000 Plan, a complete liquidation of the Company; or</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>under the 1999 Plan only, at least a majority of the directors of the Company constitute
persons who were not at the time of their first election to the Board of Directors,
candidates proposed by a majority of the Board of Directors in office prior to the time of
such first election.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U>2007 Performance Incentive Plan</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Under the 2007 Performance Incentive Plan (&#147;2007 Plan&#148;), in the event of a change of control, the
administrator has the discretion to provide in each award agreement the terms and conditions that
relate to (1)&nbsp;the vesting of an award and (2)&nbsp;the assumption of an award or issuance of comparable
securities under an incentive program. If the terms of an option agreement provide for accelerated
vesting in the event of a change of control, or to the extent that an option is vested and not yet
exercised, the administrator may provide for the purchase or exchange of each option for an amount
of cash or other property. Outstanding options shall terminate and cease to be exercisable upon a
change of control except to the extent that the options are assumed by the successor entity (or
parent thereof) pursuant to the terms of the change of control transaction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As used in the 2007 Plan, the term &#147;change of control&#148; means the occurrence of any of the
following:
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the acquisition, directly or indirectly, in one transaction or a series of related
transactions, by any person or group of the beneficial ownership of securities of the
Company possessing more than 50% of the total combined voting power of all outstanding
securities of the Company;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a merger or consolidation of the Company with any other entity, whether or not the
Company is the surviving entity in such transaction, except for a transaction in which the
holders of the outstanding voting securities of the Company immediately prior to such
merger or consolidation hold as a result of holding Company securities prior to such
transaction, in the aggregate, securities possessing more than 50% of the total combined
voting power of all outstanding voting securities of the Company or of the surviving entity
(or the parent of the surviving entity) immediately after such merger or consolidation;</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the sale, transfer or other disposition (in one transaction or a series of related
transactions) of all or substantially all of the assets of the Company; or</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 10pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the approval by the stockholders of a plan or proposal for the liquidation or
dissolution of the Company.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV style="margin-top: 10pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">


</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U>OncoGenex Technologies Inc. Amended and Restated Stock Option Plan</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Under the OncoGenex Technologies Inc. Amended and Restated Stock Option Plan (the &#147;OTI Plan&#148;), if a
change of control occurs, then 50% (or such larger percentage as may be determined by the Board of
Directors) of all shares subject to each outstanding stock option that have not yet vested shall
vest and become exercisable. Additionally, if an optionee, our stockholders generally or a class of
our stockholders that includes the optionee receive an offer for shares that, if accepted, would
result in a change of control, all shares subject to options held by officers and directors will
become exercisable so as to permit the optionee to tender such shares pursuant to the offer. If the
offer is not completed, the optionee may be able to return to the shares received upon such
exercise and reinstate the option. Upon proper notice of the offer, our Board of Directors may also
accelerate an option&#146;s expiration date so that all options will either be exercised or will expire
prior to the date on which shares must be tendered pursuant to the offer.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As used in the OTI Plan, a change of control means the acquisition of voting securities of the
Company by a person or a person and a joint actor, that, when added to all other voting securities
of the Company at the time held by such person or persons, totals for the first time not less than
50% of the outstanding voting securities of the Company or the votes attached to those securities
are sufficient, if exercised, to elect a majority of the Board of Directors of the Company.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Termination and Change of Control Provisions Under Employment Agreements</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">As of December&nbsp;31, 2008, we have employment agreements in place with each of our Named Executive
Officers that provide for compensation upon the termination of their employment under certain
circumstances. In addition, Mr.&nbsp;Cormack&#146;s and Mr.&nbsp;Anderson&#146;s agreements provide for compensation in
the event of a change of control. Information concerning the specific termination and change of
control arrangements with each of our Named Executive Officers is set forth below. During 2009, the
Company intends to amend and restate each of the employment agreements currently in place with our
Named Executive Officers.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U>Scott Cormack</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Pursuant to our employment agreement with Mr.&nbsp;Cormack, if we terminate Mr.&nbsp;Cormack&#146;s employment
without just cause, or if Mr.&nbsp;Cormack resigns following any material adverse change, without his
prior written consent, in his title, status, position, job function, compensation or reporting
responsibilities (&#147;Constructive Dismissal&#148;), we are obligated to pay to him a lump sum or
continuance of salary of 12&nbsp;months of his compensation, calculated based on the average of the base
salary plus bonus paid to him in the prior two year period. Any stock options granted to Mr.
Cormack shall, to the extent already vested at the time of termination, be exercisable until the
earlier of the expiry date of such options or the 365th day after his termination or constructive
dismissal.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In addition, in the event of a change of control, one-half of any then-unvested options owned by
Mr.&nbsp;Cormack shall automatically vest. If Mr.&nbsp;Cormack is terminated without just cause after such
change of control, all remaining unvested options shall automatically vest. As used in Mr.
Cormack&#146;s employment agreement, the term &#147;change of control&#148; has the same meaning as such term has
under the OTI Plan, which is set forth above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In the event of termination under any of the foregoing circumstances, and to the extent that the
insurance plans permit, Mr.&nbsp;Cormack will also have continued entitlement under all group medical,
dental and insurance plans, excluding short and long term disability plans and pension plan until
the earlier of the date that is 12&nbsp;months after termination or the date he becomes employed
elsewhere with comparable benefits. To the extent the continuance of certain benefit plans is not
permitted, including short and long term disability, the Company will pay to Mr.&nbsp;Cormack, no later
than 30&nbsp;days after termination, 15% of his base salary in effect immediately prior to the
termination for 12&nbsp;months.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U>Stephen Anderson</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Under our employment agreement with Mr.&nbsp;Anderson, if we terminate Mr.&nbsp;Anderson for reasons other
than for just cause, or if Mr.&nbsp;Anderson resigns as a result of a Constructive Dismissal, he shall
be entitled to (1)&nbsp;four weeks notice plus an additional two weeks for each full year of employment,
up to a maximum of 26&nbsp;weeks (&#147;Anderson Severance Period&#148;) or (2)&nbsp;a payment in lieu of notice in an
amount determined by multiplying his average weekly earnings (inclusive of base salary and bonus)
by the number of weeks in the Anderson Severance Period, calculated based on the average of the
base salary plus bonus paid to him in the prior two year period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In the event of a change of control resulting from a merger or acquisition with another entity, and
Mr.&nbsp;Anderson is terminated in connection therewith, Mr.&nbsp;Anderson shall be entitled to severance in
an amount equal to 12&nbsp;months determined by multiplying his average weekly earnings (inclusive of
base salary and bonus) by 52&nbsp;weeks, calculated based on the average of the base salary plus bonus
paid to him in the prior two year period.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The amounts paid pursuant to any of the foregoing may be paid either in a lump sum or by equal
weekly, semi-monthly or monthly installments for the number of months such benefits last, at the
Company&#146;s sole discretion.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In the event of termination under any of the foregoing circumstances, and to the extent that the
insurance plans permit, Mr.&nbsp;Anderson will also have continued entitlement to all group medical,
dental and insurance plans, excluding short and long term disability plans and pension plan until
the earlier of the expiration of the Anderson Severance Period or the date he becomes employed
elsewhere with comparable benefits. To the extent the continuance of certain benefit plans,
excluding short and long term disability, is not permitted, the Company shall pay to Mr.&nbsp;Anderson,
no later than 30&nbsp;days after termination, 10% of his weekly base salary in effect immediately prior
to termination multiplied by the number of weeks in the Anderson Severance Period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U>Cindy Jacobs</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Under our employment agreement with Dr.&nbsp;Jacobs, if we terminate Dr.&nbsp;Jacobs&#146; employment without
cause, we are obligated to pay her severance pay equal to 12&nbsp;months of her then-current base
salary, provided that Dr.&nbsp;Jacobs&#146; and the Company execute a mutual general release of claims that
is not subsequently rescinded. In connection with such termination, Dr.&nbsp;Jacobs will have no rights
to any unvested benefits or any other compensation or payments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Our employment agreement with Dr.&nbsp;Jacobs does not contain a change of control provision.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Potential Cost of Termination Payments in the Event of Termination not in Connection with a Change
of Control</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In the table below, we have estimated the potential cost to us of the compensation, excluding
compensation in connection with a change of control, to which each Named Executive Officer would
have been entitled if his or her employment had been terminated either without cause or due to
Constructive Dismissal, as applicable, effective December&nbsp;31, 2008.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="58%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left"><B>Named</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2"><B>Cash</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Executive Officer</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Severance</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Benefits</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 1px solid #000000"><B>Total</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Scott Cormack (1)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">366,029</TD>
    <TD nowrap>(2)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">447</TD>
    <TD nowrap>(2)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">336,476</TD>
    <TD nowrap>(2)</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Stephen Anderson (1)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">28,712</TD>
    <TD nowrap>(2)(3)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">407</TD>
    <TD nowrap>(2)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">29,119</TD>
    <TD nowrap>(2)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff; padding-top: 1px">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cindy Jacobs (1)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">346,800</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">948</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">347,748</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>




<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR style="font-size: 6pt">
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="96">&nbsp;</TD>
</TR>
<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>Mr.&nbsp;Cormack and Mr.&nbsp;Anderson would have been entitled to the compensation in this chart in the
event of either a termination without just cause or due to a Constructive Dismissal, whereas Dr.
Jacobs would have been entitled to the compensation in this chart only in the event of a
termination without cause.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>Amounts payable to Mr.&nbsp;Cormack and Mr.&nbsp;Anderson are denominated in Canadian dollars and have
been translated into U.S. dollars based on the December&nbsp;31, 2008 exchange rate of US$1.00 =
CAD$1.224.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>The amount provided assumes that the Company paid a cash severance in lieu of notice, as
described above under the heading &#147;Termination and Change of Control Provisions Under Employment
Agreements &#151; Stephen Anderson.&#148;</TD>
</TR>

</TABLE>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Potential Cost of Change of Control Benefits</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U>Non-equity Compensation</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In the event of a change of control pursuant to which Mr.&nbsp;Cormack is terminated, Mr.&nbsp;Cormack would
be entitled to all of the non-equity compensation set forth in the table above.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">In the event of a change of control pursuant to which Mr.&nbsp;Anderson is terminated, Mr.&nbsp;Anderson
would be entitled to the following non-equity compensation: (1) $228,436, which is equal to
one-half of the salary and bonus earned in the last two years and (2)&nbsp;the amount set forth in the
table above in respect of benefits.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Dr.&nbsp;Jacobs would be entitled to no non-equity compensation in the event of a change of control.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><U>Equity Compensation</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">All of Mr.&nbsp;Cormack&#146;s and Dr.&nbsp;Jacobs&#146; stock options outstanding as of December&nbsp;31, 2008 that had
been granted under the OTI Plan had vested as of December&nbsp;31, 2008, and therefore, no additional
benefit would accrue to such officers under the OTI Plan in connection with a change of control.
All of their respective remaining outstanding stock options as of December&nbsp;31, 2008 were granted
under the 2000 Plan. Because the administrator under the 2000 Plan has the discretion to determine
the effect of a change of control on outstanding stock options, the resulting change of control
benefit, if any, provided for by the 2000 Plan cannot be
quantified. However, due to provisions in Mr.&nbsp;Cormack&#146;s employment agreement, in the event of a
change of control as of December&nbsp;31, 2008: (1)&nbsp;50,000 of Mr.&nbsp;Cormack&#146;s 100,000 stock options then
outstanding under the 2000 Stock Incentive Plan would have vested immediately, resulting in a cost
to the Company equal to $97,937; and (2)&nbsp;if Mr.&nbsp;Cormack had been terminated without just cause
following such change of control, the remaining 50,000 unvested stock options would have vested
immediately, resulting in a cost to the Company equal to $97,937.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Of Mr.&nbsp;Anderson&#146;s stock options to purchase 61,776 shares of common stock under the OTI Plan,
16,332 had vested as of December&nbsp;31, 2008, and therefore, no additional benefit would accrue to him
with respect thereto in connection with a change of control. However, as of December&nbsp;31, 2008,
stock options to purchase 45,444 shares of common stock under the OTI Plan had not yet vested. A
minimum of 50% of these options, or such larger percentage determined by the Board of Directors,
would immediately vest upon a change of control. Assuming a change of control as of December&nbsp;31,
2008, the cost to the Company in connection with the resulting accelerated vesting of 50% of Mr.
Anderson&#146;s unvested options would have been equal to $39,001. Additionally, if our stockholders
generally or a class of our stockholders that included Mr.&nbsp;Anderson were to have received and
accepted an offer for shares that resulted in a change of control as of December&nbsp;31, 2008, all of
Mr.&nbsp;Anderson&#146;s remaining unvested stock options would have vested immediately, resulting in an
additional cost to the Company equal to $39,001.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><I>Actual 2008 Change of Control/Termination Benefits</I>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">The Summary Compensation Table provides information regarding the actual change of
control/termination benefits provided to our previous Chief Executive Officer and President,
Michael Martino, and our previous Chief Financial Officer, Alan Fuhrman, in connection with the
Arrangement.
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<DIV align="left">
<A name="145"></A>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 10pt"><B>OTHER MATTERS</B>
</DIV>

<DIV align="left">
<A name="146"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Section&nbsp;</B><B>16(a)</B><B> Beneficial Ownership Reporting Compliance</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Section&nbsp;16(a) of the Exchange Act requires that our executive officers and directors, and persons
who own more than 10% of a registered class of our equity securities, file reports of ownership and
changes in ownership with the SEC. Executive officers, directors and greater than 10% stockholders
are required by SEC rules to furnish us with copies of all forms they file. Based solely on our
review of the copies of such forms we received and written representations from certain reporting
persons, we believe that all Section 16(a) filing requirements applicable to our executive
officers, directors and 10% stockholders were complied with during fiscal year 2008.
</DIV>
<DIV align="left">
<A name="147"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Delivery of Documents to Stockholders Sharing an Address</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">We have adopted a process for delivering documents to stockholders approved by the SEC called
&#147;householding.&#148; Under this process, stockholders of record who have the same address and last name
will receive only one copy of our annual report and this Proxy Statement, unless we or one of our
mailing agents has received contrary instructions from any stockholder at that address. We will
continue to mail a proxy card to each stockholder of record.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If you prefer to receive multiple copies of the Annual Report and Proxy Statement at the same
address, additional copies will be provided to you promptly upon request. If you are a stockholder
of record, you may contact us by writing to OncoGenex Pharmaceuticals, Inc., Attention: Investor
Relations, 1522 217th Place S.E., Bothell, Washington 98021. Eligible stockholders of record
receiving multiple copies of our annual report and this Proxy Statement can request householding by
contacting us in the same manner.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If you are a beneficial owner holding shares through your broker, bank or other nominee, you may
request additional copies of the Annual Report or Proxy Statement or you may request householding
by notifying your broker, bank or nominee.
</DIV>
<DIV align="left">
<A name="148"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Stockholder Proposals to be Presented at Next Annual Meeting</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Proposals of stockholders that are intended for inclusion in our proxy statement relating to the
2010 Annual Meeting must be received by us at our offices at 1522 217th Place S.E., Bothell,
Washington 98021, no later than December&nbsp;15, 2009, which corresponds to the date that is 120
calendar days before the anniversary date on which our proxy statement was released to stockholders
in connection with this year&#146;s Annual Meeting. If the date is changed by more than 30 calendar days
from the anniversary date of this year&#146;s Annual Meeting, then the deadline is a reasonable time
before we begin to print and mail proxy materials. Such proposals must satisfy the conditions
established by the SEC, including, but not limited to, Rule&nbsp;14a-8 promulgated under the Exchange
Act in order to be included in our proxy statement for that meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Stockholder proposals, other than those in respect of nominations for the Company&#146;s Board of
Directors, that are not intended to be included in our proxy materials for our 2010 Annual Meeting
but that are intended to be presented by the stockholder from the floor must be received at our
offices at 1522 217th Place S.E., Bothell, Washington 98021 no later than February&nbsp;27, 2010, which
corresponds to the date that is 45 calendar days before the anniversary date on which our proxy
statement was released to stockholders in connection with this year&#146;s Annual Meeting. If the date
of our 2010 Annual Meeting is changed by more than 30 calendar days from the anniversary date of
this year&#146;s Annual Meeting, then the deadline is a reasonable time before we send our proxy
materials for that meeting.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">If a stockholder wishes to nominate a person for election to the Board of Directors, such
stockholder must follow the procedures set forth under the section entitled &#147;Board of Directors &#151;
Director Nomination Process &#151; Stockholder Nominations.&#148;
</DIV>
<DIV align="left">
<A name="149"></A>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt"><B>Transaction of Other Business</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">At the date of this Proxy Statement, the only business that the Board of Directors intends to
present or knows that others will present at the Annual Meeting is as set forth above. If any other
matter or matters are properly brought before the Annual Meeting, or any adjournment or
postponement thereof, it is the intention of the persons named in the accompanying form of proxy to
vote the proxy on such matters in accordance with their best judgment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 10pt">By Order of the Board of Directors,
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 10pt">Stephen Anderson<BR>
Secretary<BR>
Bothell, Washington<BR>
April&nbsp;13, 2009

</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#tocpage">Table of Contents</A></H5><P>


<DIV style="font-family: Helvetica,Arial,sans-serif; margin-left: .25in; width: 7.20in">

<P><DIV style="position: relative; float: left; width: 47%">

<DIV align="justify" style="font-size: 8pt; margin-top: 10pt"><B><I>LOGO</I></B>
</DIV>


<DIV align="left" style="font-size: 8pt; margin-top: 10pt"><B><I>OncoGenex<BR>
Pharmaceuticals, Inc.<BR>
C/O PROXY SERVICES<BR>
P.O. BOX 9142<BR>
FARMINGDALE, NY 11735</I></B>

</DIV>
</DIV>
<DIV style="position: relative; float: right; width: 47%">

<DIV align="justify" style="font-size: 8pt; margin-top: 10pt"><B>VOTE BY INTERNET &#151; </B><U><B>www.proxyvote.com</B></U>
</DIV>


<DIV align="justify" style="font-size: 8pt">Use the Internet to transmit your voting instructions and for electronic delivery of
information up until 11:59&nbsp;P.M. Eastern Time the day before the cut-off date or meeting date.
Have your proxy card in hand when you access the web site and follow the instructions to
obtain your records and to create an electronic voting instruction form.
</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 10pt"><B>ELECTRONIC DELIVERY OF FUTURE SHAREHOLDER COMMUNICATIONS</B>
</DIV>


<DIV align="justify" style="font-size: 8pt">If you would like to reduce the costs incurred by OncoGenex Pharmaceuticals, Inc. in
mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards
and annual reports electronically via e-mail or the Internet. To sign up for electronic
delivery, please follow the instructions above to vote using the Internet and, when prompted,
indicate that you agree to receive or access shareholder communications electronically in
future years.
</DIV>

<DIV align="justify" style="font-size: 8pt; margin-top: 10pt"><B>VOTE BY PHONE &#151; 1-800-690-6903</B>
</DIV>


<DIV align="justify" style="font-size: 8pt">Use any touch-tone telephone to transmit your voting instructions up until 11:59&nbsp;P.M. Eastern Time
the day before the cut-off date or meeting date. Have your proxy card in hand when you call and
then follow the instructions.
</DIV>

<DIV align="justify" style="font-size: 8pt; margin-top: 10pt"><B>VOTE BY MAIL</B>
</DIV>


<DIV align="justify" style="font-size: 8pt">Mark, sign and date your proxy card and return it in the postage-paid envelope we have
provided or return it to OncoGenex Pharmaceuticals, Inc. c/o Broadridge, 51 Mercedes Way, Edgewood,
NY 11717.
</DIV>
</DIV>
<BR clear="all"><BR>
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="48%"></TD>
    <TD width="3%"></TD>
    <TD width="48%"></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom" style="font-size: 40pt">
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top" nowrap>TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">KEEP THIS PORTION FOR YOUR RECORDS</TD>
</TR>
<TR valign="bottom" style="font-size: 1px">
    <TD align="left" valign="top" nowrap colspan="3"><DIV style="border-top: 1px dashed #000000">&nbsp;</DIV>
</TD>
</TR>

<TR valign="bottom">
    <TD align="left" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top">DETACH AND RETURN THIS PORTION ONLY</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<div style="margin-top: 3pt">
<DIV style="width: 100%; border: 3px solid black; padding: 3px;">
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom" style="font-size: 1px">
    <TD width="75%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>OncoGenex Pharmaceuticals, Inc.</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD colspan="2" valign="top"><DIV style="margin-right: 2%; text-indent:-0px" align="justify">The undersigned hereby nominates, constitutes and appoints Scott Cormack and Stephen Anderson, and
each of them individually, the attorney, agent and proxy of the undersigned, with full power of
substitution, to vote all stock of ONCOGENEX PHARMACEUTICALS, INC., which the undersigned is
entitled to represent and vote at the Annual Meeting of Stockholders of the Company to be held at
the Sheraton Seattle Hotel, 1400 Sixth Avenue, Seattle, Washington, on May&nbsp;12, 2009 at 10:00&nbsp;A.M.
local time, and at any and all adjournments or postponements thereof, as fully as if the
undersigned were present and voting meeting, as follows:</DIV></TD>

    <TD align="left" valign="top" colspan="1"><DIV style="border-top: 3px solid #000000; border-right: 3px solid #000000"><br><br>&nbsp;</DIV></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<div style="margin-top: 6pt"><DIV style="position: relative; float: left; width: 42%">

<DIV align="justify" style="font-size: 8pt; margin-top: 1pt"><B>THE BOARD OF DIRECTORS RECOMMEND A VOTE &#147;FOR&#148; ITEMS 1 AND 2.</B>
</DIV>

<DIV align="justify" style="font-size: 8pt; margin-top: 10pt"><B>Vote on Directors</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">1.</TD>
    <TD>&nbsp;</TD>
    <TD colspan="9" nowrap valign="top" align="left">ELECTION OF DIRECTORS</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="9" nowrap valign="top" align="left"><B>Nominees:</B></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" colspan="2">01)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Scott Cormack
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">04)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Neil Clendeninn</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" colspan="2">02)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" nowrap>Michelle G. Burris
</TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" colspan="2">05)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Patrick R. Brady</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right" valign="top" colspan="2">03)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dwight Winstead
</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">06)</TD>
    <TD nowrap valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Michael A. Martino</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

</DIV>
<DIV style="position: relative; float: right; width: 56%">
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" align="center"><B>For <BR>
All</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>Withhold<BR>
All</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>For All<BR>
Except</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV align="justify">To withhold authority to vote for any
individual nominee(s), mark &#147;For All
Except&#148; and write the number(s) of the
nominee(s) on the line below.</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top" align="center"><FONT face="Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT face="Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="border-bottom: 1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD colspan="7" valign="top" align="left"><DIV align="justify">To cumulate votes as to a particular nominee(s) as explained in the Proxy Statement, indicate the name(s) and the number of votes to be given to such nominee(s).</div></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD colspan="5" valign="top" align="left">Cumulate</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><DIV style="border-bottom: 1px solid #000000">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>
</DIV>
</DIV>
<BR clear="all"><BR>
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="80%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Vote on Proposals</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>For</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Against</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Abstain</B></TD>
</TR>
<TR>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV align="justify">2. Proposal to ratify the appointment of Ernst &#038; Young
LLP as our independent auditor for the fiscal year
ending December&nbsp;31, 2009.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT face="Wingdings">&#111;</FONT></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV align="justify">The shares represented by
this proxy when properly executed will be voted
in the manner directed herein by the
undersigned Stockholder(s). <B>If no
direction is made, this proxy will be voted
FOR items 1 and 2.</B> If any other matters
properly come before the meeting, the person
named in this proxy will vote in their
discretion.</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<P><DIV style="position: relative; float: left; width: 47%">
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="77%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="5"><DIV style="margin-left:0px; text-indent:-0px">For address changes and/or comments, please check this box and write them on the back where indicated. <FONT face="Wingdings">&#111;</FONT></DIV></TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="84%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Yes</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>No</B></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Please indicate if you plan to attend this meeting.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><FONT face="Wingdings">&#111;</FONT>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"> <FONT face="Wingdings">&#111;</FONT></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px" align="justify"><B>Please complete, sign, date and return the Proxy Card
promptly using the enclosed envelope.</B></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom" style="font-size: 19pt">
    <TD width="85%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="border-left: 1px solid #000000; border-top: 1px solid #000000; border-bottom: 2px solid #000000; border-right: 0px solid #000000"><br>&nbsp;</DIV></TD>
    <TD align="left" valign="top" colspan="2"><DIV style="border-left: 1px solid #000000; border-top: 1px solid #000000; border-bottom: 2px solid #000000; border-right: 1px solid #000000"><br>&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature &#091;PLEASE SIGN WITHIN BOX&#093;
</DIV></TD>
    <TD align="left" valign="top" colspan="2">Date</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

</DIV>
<DIV style="position: relative; float: right; width: 44%">

<DIV align="justify" style="font-size: 8pt; margin-top: 10pt; margin-bottom: 2%; margin-right: 40%">Please sign your name exactly as it appears hereon. When signing as attorney, executor,
administrator, trustee or guardian, please add your title as such. When signing as joint
tenants, all parties in the joint tenancy must sign. If a signer is a corporation, please sign in
full corporate name by duly authorized officer and state your title.
</DIV>
<DIV align="center">
<TABLE style="font-size: 8pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head --><TR valign="bottom">
    <TD width="85%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="border-left: 1px solid #000000; border-top: 1px solid #000000; border-bottom: 2px solid #000000; border-right: 0px solid #000000"><br>&nbsp;</DIV></TD>
    <TD align="left" valign="top" colspan="2"><DIV style="border-left: 1px solid #000000; border-top: 1px solid #000000; border-bottom: 2px solid #000000; border-right: 1px solid #000000"><br>&nbsp;</DIV></TD>
</TR>
<TR valign="bottom" style="padding-top: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Signature (Joint Owners)
</DIV></TD>
    <TD align="left" valign="top" colspan="2">Date</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>

</DIV>
<BR clear="all"><br style="font-size: 6pt">
</DIV>
</DIV>



<P align="center" style="font-size: 8pt">&nbsp;

<P align="center" style="font-size: 8pt"><!-- Folio --><!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
